Identification

Name
Prednisolone
Accession Number
DB00860  (APRD00197)
Type
Small Molecule
Groups
Approved, Vet approved
Description

A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]

Structure
Thumb
Synonyms
  • (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
  • 1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
  • 1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
  • 3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
  • delta-dehydrocortisol
  • delta-dehydrohydrocortisone
  • delta-hydrocortisone
  • delta(1)-Dehydrocortisol
  • delta(1)-Dehydrohydrocortisone
  • delta(1)-Hydrocortisone
  • Hydroretrocortine
  • Metacortandralone
  • PRDL
  • Prednisolona
  • Prednisolonum
External IDs
NSC-9120 / NSC-9900
Product Ingredients
IngredientUNIICASInChI Key
Prednisolone 21-phosphate752SY38R6C302-25-0JDOZJEUDSLGTLU-VWUMJDOOSA-N
Prednisolone acetate8B2807733D52-21-1LRJOMUJRLNCICJ-JZYPGELDSA-N
Prednisolone sodium phosphateIV021NXA9J125-02-0VJZLQIPZNBPASX-OJJGEMKLSA-L
prednisolone sodium succinate8223RR9DWF1715-33-9FKKAEMQFOIDZNY-CODXZCKSSA-M
Prednisolone tebutate1V7A1U282K7681-14-3HUMXXHTVHHLNRO-KAJVQRHHSA-N
Prednisolone tertiary butylacetateNot AvailableNot AvailableNot applicable
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ak Tate Oph Sus 1%Suspension1 %OphthalmicSandoz Canada Incorporated1985-12-312008-08-07Canada
Diopred Suspension 1%Suspension1 %OphthalmicSandoz Canada Incorporated1994-12-31Not applicableCanada
Flo-PredSuspension15 mg/5mLOralTaro Pharmaceuticals U.S.A., Inc.2008-01-17Not applicableUs
Inflamase Forte Oph Soln 1%Liquid10 mgOphthalmicIolab Pharmaceuticals1988-12-311996-09-09Canada
Inflamase Forte Ophthalmic Solution 1%Solution1 %OphthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1996-08-202004-07-13Canada
Inflamase MildLiquid.125 %OphthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1995-12-312002-07-04Canada
Inflamase Oph Soln 0.125%Liquid1.25 mgOphthalmicIolab Pharmaceuticals1988-12-311996-09-09Canada
Minims Prednisolone Sodium Phosphate 0.5%Solution / drops0.5 %OphthalmicValeant Canada Lp Valeant Canada S.E.C.1995-12-31Not applicableCanada
OmnipredSuspension10 mg/mLOphthalmicAlcon, Inc.2007-11-06Not applicableUs
Orapred ODTTablet, orally disintegrating15 mg/1OralShionogi2006-06-012016-10-13Us59630 0701 48 nlmimage10 d916ec97
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MillipredTablet5 mg/1OralZylera Pharmaceuticals, LLC2014-03-01Not applicableUs
MillipredSolution10 mg/5mLOralLaser Pharmaceuticals Llc2009-07-012018-01-06Us
MillipredSolution10 mg/5mLOralZylera Pharmaceuticals, LLC2014-03-01Not applicableUs
MillipredTablet5 mg/5mgOralLaser Pharmaceuticals Llc2008-10-012017-12-22Us16477 0505 01 nlmimage10 851b42ca
Novo-prednisolone 5mgTablet5 mgOralNovopharm Limited1967-12-312005-08-10Canada
OrapredSolution15 mg/5mLOralShionogi2000-12-142016-02-22Us
PediapredSolution5 mg/5mLOralRoyal Pharmaceuticals2003-03-262018-03-22Us
PMS-prednisoloneSolution5 mgOralPharmascience Inc2002-03-19Not applicableCanada
PMS-prednisolone Sodium Phosphate Ophthalmic Solution ForteSolution1 %OphthalmicPharmascience Inc1992-12-31Not applicableCanada
PrednisoloneSolution15 mg/5mLOralApotheca, Inc.2003-02-27Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
BlephamidePrednisolone acetate (2 mg/mL) + Sulfacetamide sodium (100 mg/mL)Suspension / dropsOphthalmicA S Medication Solutions1961-10-012017-06-20Us
BlephamidePrednisolone acetate (2 mg/g) + Sulfacetamide sodium (100 mg/g)OintmentOphthalmicAllergan1987-01-01Not applicableUs
BlephamidePrednisolone acetate (2 mg/mL) + Sulfacetamide sodium (100 mg/mL)Suspension / dropsOphthalmicPhysicians Total Care, Inc.1961-10-01Not applicableUs
BlephamidePrednisolone acetate (2 mg/g) + Sulfacetamide sodium (100 mg/g)OintmentOphthalmicA S Medication Solutions1987-01-012017-06-20Us
BlephamidePrednisolone acetate (2 mg/mL) + Sulfacetamide sodium (100 mg/mL)Suspension / dropsOphthalmicAllergan1961-10-01Not applicableUs
BlephamidePrednisolone acetate (2 mg/g) + Sulfacetamide sodium (100 mg/g)OintmentOphthalmicPhysicians Total Care, Inc.2012-03-04Not applicableUs
Blephamide Oph OntPrednisolone acetate (0.2 %) + Sulfacetamide sodium (10 %)OintmentOphthalmicAllergan1974-12-31Not applicableCanada
Blephamide Opht SuspensionPrednisolone acetate (0.2 %) + Sulfacetamide sodium (10 %)Solution / dropsOphthalmicAllergan1989-12-31Not applicableCanada
Dioptimyd OintmentPrednisolone acetate (5 mg) + Sulfacetamide sodium (100 mg)OintmentOphthalmic; TopicalEberth Pharmaceuticals Inc1994-12-31Not applicableCanada
Metimyd Oph SusPrednisolone acetate (5 mg) + Sulfacetamide sodium (100 mg)SuspensionOphthalmicSchering Plough1956-12-311999-07-22Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Pred Phos - BromPrednisolone sodium phosphate (10 mg/mL) + Bromfenac sodium (.75 mg/mL)Solution / dropsOphthalmicImprimis Njof, Llc2018-07-02Not applicableUs
Pred Phos - GatiPrednisolone sodium phosphate (10 mg/mL) + Gatifloxacin (5 mg/mL)Solution / dropsOphthalmicImprimis Njof, Llc2018-07-02Not applicableUs
Pred Phos-Gati-BromPrednisolone sodium phosphate (10 mg/mL) + Bromfenac (.75 mg/mL) + Gatifloxacin (5 mg/mL)Solution / dropsOphthalmicImprimis Njof, Llc2018-07-02Not applicableUs
Pred-BromPrednisolone acetate (10 mg/mL) + Bromfenac (.75 mg/mL)Suspension / dropsOphthalmicImprimis Rx Nj2018-02-01Not applicableUs
Pred-BromPrednisolone acetate (10 mg/mL) + Bromfenac sodium (.75 mg/mL)Suspension / dropsOphthalmicImprimis Njof, Llc2018-01-05Not applicableUs
Pred-GatiPrednisolone acetate (10 mg/mL) + Gatifloxacin (5 mg/mL)Suspension / dropsOphthalmicImprimis Njof, Llc2018-01-05Not applicableUs
Pred-GatiPrednisolone acetate (10 mg/mL) + Gatifloxacin hemihydrate (5 mg/mL)SuspensionOphthalmicImprimis Rx Nj2018-03-01Not applicableUs
Pred-Gati-BromPrednisolone acetate (10 mg/mL) + Bromfenac (.75 mg/mL) + Gatifloxacin (5 mg/mL)Suspension / dropsOphthalmicImprims Njof, Llc2018-01-05Not applicableUs
Pred-Gati-BromPrednisolone acetate (10 mg/mL) + Bromfenac sodium (.75 mg/mL) + Gatifloxacin (5 mg/mL)Suspension / dropsOphthalmicImprimis Njof, Llc2018-01-12Not applicableUs
Pred-Gati-BromPrednisolone acetate (10 mg/mL) + Bromfenac (.75 mg/mL) + Gatifloxacin hemihydrate (5 mg/mL)Suspension / dropsOphthalmicImprimis Rx Nj2018-01-01Not applicableUs
International/Other Brands
Ak-Pred / Decortin H / Delta-Cortef / Deltacortril / Hydeltra / Hydeltra-TBA / Hydeltrasol / Inflamase / Key-Pred / Klismacort / Meticortelone / Panafcortelone / Precortalon / Predonine / Prelone / Solone / Sterolone / Ultracortenol
Categories
UNII
9PHQ9Y1OLM
CAS number
50-24-8
Weight
Average: 360.444
Monoisotopic: 360.193674006
Chemical Formula
C21H28O5
InChI Key
OIGNJSKKLXVSLS-VWUMJDOOSA-N
InChI
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
IUPAC Name
(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C

Pharmacology

Indication

For the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders.

Associated Conditions
Pharmacodynamics

Prednisolone is a synthetic glucocorticoid used as antiinflammatory or immunosuppressive agent. Prednisolone is indicated in the treatment of various conditions, including congenital adrenal hyperplasia, psoriatic arthritis, systemic lupus erythematosus, bullous dermatitis herpetiformis, seasonal or perennial allergic rhinitis, allergic corneal marginal ulcers, symptomatic sarcoidosis, idiopathic thrombocytopenic purpura in adults, leukemias and lymphomas in adults, and ulcerative colitis. Glucocorticoids are adrenocortical steroids and cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

Mechanism of action

Glucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.

TargetActionsOrganism
AGlucocorticoid receptor
agonist
Human
Absorption

Readily absorbed by gastrointestinal tract, peak plasma concentration is reached 1-2 hours after administration.

Volume of distribution
Not Available
Protein binding

Very high (>90%)

Metabolism

Excreted in the urine as either free or glucoconjugate.

Route of elimination
Not Available
Half life

2-3 hours

Clearance
Not Available
Toxicity

LD50=500 mg/kg (oral, rat), short-term side effects include high blood glucose levels and fluid retention. Long term side effects include Cushing's syndrome, weight gain, osteoporosis, glaucoma, type II diabetes and adrenal suppression.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Prednisone Action PathwayDrug action
Prednisone Metabolism PathwayDrug metabolism
Prednisolone Action PathwayDrug action
Prednisolone Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1-TestosteroneThe risk or severity of edema formation can be increased when 1-Testosterone is combined with Prednisolone.Experimental, Illicit, Investigational
1,10-PhenanthrolineThe therapeutic efficacy of 1,10-Phenanthroline can be decreased when used in combination with Prednisolone.Experimental
16-BromoepiandrosteroneThe risk or severity of edema formation can be increased when 16-Bromoepiandrosterone is combined with Prednisolone.Investigational
19-norandrostenedioneThe risk or severity of edema formation can be increased when 19-norandrostenedione is combined with Prednisolone.Experimental, Illicit
1alpha-Hydroxyvitamin D5The therapeutic efficacy of 1alpha-Hydroxyvitamin D5 can be decreased when used in combination with Prednisolone.Investigational
2-MethoxyethanolThe risk or severity of adverse effects can be increased when Prednisolone is combined with 2-Methoxyethanol.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of 2,4-thiazolidinedione can be decreased when used in combination with Prednisolone.Investigational
4-HydroxytestosteroneThe risk or severity of edema formation can be increased when 4-Hydroxytestosterone is combined with Prednisolone.Experimental, Illicit
5-androstenedioneThe risk or severity of edema formation can be increased when 5-androstenedione is combined with Prednisolone.Experimental, Illicit
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of adverse effects can be increased when Prednisolone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.Investigational
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Prednisolone.Approved
AbediterolThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Abediterol.Investigational
AbemaciclibThe serum concentration of Prednisolone can be increased when it is combined with Abemaciclib.Approved, Investigational
AbetimusThe risk or severity of adverse effects can be increased when Prednisolone is combined with Abetimus.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Prednisolone.Approved, Investigational
AceclofenacThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Acemetacin.Approved, Experimental, Investigational
AcetaminophenThe serum concentration of Prednisolone can be increased when it is combined with Acetaminophen.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Prednisolone.Approved, Investigational, Withdrawn
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prednisolone.Approved, Vet Approved
ActeosideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Acteoside.Investigational
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Prednisolone.Approved
AfatinibThe serum concentration of Prednisolone can be increased when it is combined with Afatinib.Approved
AfelimomabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Afelimomab.Investigational
AICA ribonucleotideThe therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Prednisolone.Experimental, Investigational
AlbendazoleThe serum concentration of Prednisolone can be increased when it is combined with Albendazole.Approved, Vet Approved
AlbiglutideThe therapeutic efficacy of Albiglutide can be decreased when used in combination with Prednisolone.Approved
AlclofenacThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Alclometasone.Approved
AlcuroniumThe risk or severity of myopathy and weakness can be increased when Alcuronium is combined with Prednisolone.Experimental
AldesleukinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Aldesleukin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Aldosterone.Experimental, Investigational
AlectinibThe serum concentration of Prednisolone can be increased when it is combined with Alectinib.Approved, Investigational
AlefaceptThe risk or severity of adverse effects can be increased when Prednisolone is combined with Alefacept.Approved, Investigational, Withdrawn
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Prednisolone.Approved, Investigational
AlfacalcidolThe therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Prednisolone.Approved, Nutraceutical
AlmasilateThe bioavailability of Prednisolone can be decreased when combined with Almasilate.Approved, Experimental
AlminoprofenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Alminoprofen.Experimental
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Prednisolone.Approved
AloglutamolThe bioavailability of Prednisolone can be decreased when combined with Aloglutamol.Approved
AloxiprinThe risk or severity of adverse effects can be increased when Aloxiprin is combined with Prednisolone.Experimental
AltretamineThe risk or severity of adverse effects can be increased when Altretamine is combined with Prednisolone.Approved
AluminiumThe bioavailability of Prednisolone can be decreased when combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe bioavailability of Prednisolone can be decreased when combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe bioavailability of Prednisolone can be decreased when combined with Aluminium glycinate.Experimental
Aluminium phosphateThe bioavailability of Prednisolone can be decreased when combined with Aluminium phosphate.Approved, Investigational
Aluminum hydroxideThe bioavailability of Prednisolone can be decreased when combined with Aluminum hydroxide.Approved, Investigational
AmbenoniumThe therapeutic efficacy of Ambenonium can be decreased when used in combination with Prednisolone.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Amcinonide.Approved
AMG-222The therapeutic efficacy of AMG-222 can be decreased when used in combination with Prednisolone.Investigational
AminophenazoneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Aminophenazone.Approved, Withdrawn
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Prednisolone.Approved
AmiodaroneThe serum concentration of Prednisolone can be increased when it is combined with Amiodarone.Approved, Investigational
AmlodipineThe serum concentration of Prednisolone can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Prednisolone can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe serum concentration of Prednisolone can be increased when it is combined with Amoxapine.Approved
Amphotericin BThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Amphotericin B.Approved, Investigational
AmprenavirThe metabolism of Prednisolone can be decreased when combined with Amprenavir.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Amsacrine is combined with Prednisolone.Approved, Investigational
AnagliptinThe therapeutic efficacy of Anagliptin can be decreased when used in combination with Prednisolone.Investigational
AnakinraThe risk or severity of adverse effects can be increased when Anakinra is combined with Prednisolone.Approved
AndrostenediolThe risk or severity of edema formation can be increased when Androstenediol is combined with Prednisolone.Experimental, Illicit
AndrostenedioneThe risk or severity of edema formation can be increased when Androstenedione is combined with Prednisolone.Experimental, Illicit
AnnamycinThe serum concentration of Prednisolone can be increased when it is combined with Annamycin.Investigational
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Prednisolone.Approved
Anthrax vaccineThe risk or severity of infection can be increased when Anthrax vaccine is combined with Prednisolone.Approved
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Prednisolone.Approved
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Prednisolone.Approved, Investigational
AntipyrineThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Antipyrine.Approved, Investigational
Antithymocyte immunoglobulin (rabbit)The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Prednisolone.Approved
AntrafenineThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Antrafenine.Approved
ApalutamideThe serum concentration of Prednisolone can be decreased when it is combined with Apalutamide.Approved, Investigational
ApremilastThe risk or severity of adverse effects can be increased when Prednisolone is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Prednisolone can be increased when it is combined with Aprepitant.Approved, Investigational
ArbutamineThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Arbutamine.Approved
ArformoterolThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Arformoterol.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Prednisolone.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Arsenic trioxide.Approved, Investigational
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Prednisolone resulting in a loss in efficacy.Approved, Investigational
AstemizoleThe serum concentration of Prednisolone can be increased when it is combined with Astemizole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Prednisolone.Approved, Investigational, Withdrawn
AtamestaneThe risk or severity of edema formation can be increased when Atamestane is combined with Prednisolone.Investigational
AtazanavirThe serum concentration of Prednisolone can be increased when it is combined with Atazanavir.Approved, Investigational
AtorvastatinThe serum concentration of Prednisolone can be increased when it is combined with Atorvastatin.Approved
AtracuriumThe risk or severity of myopathy and weakness can be increased when Atracurium is combined with Prednisolone.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of myopathy and weakness can be increased when Atracurium besylate is combined with Prednisolone.Approved
AzacitidineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Azacitidine.Approved, Investigational
AzapropazoneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Azapropazone.Withdrawn
AzathioprineThe risk or severity of adverse effects can be increased when Azathioprine is combined with Prednisolone.Approved
AzelastineThe serum concentration of Prednisolone can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Prednisolone can be increased when it is combined with Azithromycin.Approved
AzosemideThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Azosemide.Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Prednisolone.Approved, Investigational
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Prednisolone.Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain danish 1331 live antigen is combined with Prednisolone.Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Prednisolone.Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Prednisolone.Approved
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Prednisolone.Approved
Bafilomycin A1The serum concentration of Prednisolone can be increased when it is combined with Bafilomycin A1.Experimental
Bafilomycin B1The serum concentration of Prednisolone can be increased when it is combined with Bafilomycin B1.Experimental
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Prednisolone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Prednisolone.Approved, Investigational
BambuterolThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Bambuterol.Approved, Investigational
BasiliximabThe risk or severity of adverse effects can be increased when Basiliximab is combined with Prednisolone.Approved, Investigational
BCG vaccineThe risk or severity of infection can be increased when BCG vaccine is combined with Prednisolone.Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Prednisolone.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Beclomethasone dipropionate.Approved, Investigational
BecocalcidiolThe therapeutic efficacy of Becocalcidiol can be decreased when used in combination with Prednisolone.Investigational
BegelomabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Begelomab.Experimental, Investigational
BelataceptThe risk or severity of adverse effects can be increased when Belatacept is combined with Prednisolone.Approved, Investigational
BelimumabThe risk or severity of adverse effects can be increased when Belimumab is combined with Prednisolone.Approved
BelinostatThe risk or severity of adverse effects can be increased when Prednisolone is combined with Belinostat.Approved, Investigational
Bempedoic acidThe therapeutic efficacy of Bempedoic acid can be decreased when used in combination with Prednisolone.Investigational
BendamustineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Bendamustine.Approved, Investigational
BendazacThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Bendazac.Experimental
BendroflumethiazidePrednisolone may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenfluorexThe therapeutic efficacy of Benfluorex can be decreased when used in combination with Prednisolone.Investigational, Withdrawn
BenorilateThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Benoxaprofen.Withdrawn
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Prednisolone.Approved, Investigational
BenzquinamideThe serum concentration of Prednisolone can be increased when it is combined with Benzquinamide.Withdrawn
BenzthiazidePrednisolone may increase the hypokalemic activities of Benzthiazide.Approved
BenzydamineThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Benzydamine.Approved
Benzyl alcoholThe serum concentration of Prednisolone can be increased when it is combined with Benzyl alcohol.Approved
BepridilThe serum concentration of Prednisolone can be increased when it is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Besifloxacin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Prednisolone.Approved, Vet Approved
BevacizumabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Bevacizumab.Approved, Investigational
BexaroteneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Bexarotene.Approved, Investigational
BicalutamideThe serum concentration of Prednisolone can be increased when it is combined with Bicalutamide.Approved
Biricodar dicitrateThe serum concentration of Prednisolone can be increased when it is combined with Biricodar dicitrate.Investigational
Bismuth subnitrateThe bioavailability of Prednisolone can be decreased when combined with Bismuth subnitrate.Approved
BitolterolThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Bitolterol.Withdrawn
BleomycinThe risk or severity of adverse effects can be increased when Bleomycin is combined with Prednisolone.Approved, Investigational
BlinatumomabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Blinatumomab.Approved, Investigational
BoceprevirThe serum concentration of Prednisolone can be increased when it is combined with Boceprevir.Approved, Withdrawn
BolandiolThe risk or severity of edema formation can be increased when Bolandiol is combined with Prednisolone.Experimental, Illicit
BolasteroneThe risk or severity of edema formation can be increased when Bolasterone is combined with Prednisolone.Experimental, Illicit
BoldenoneThe risk or severity of edema formation can be increased when Boldenone is combined with Prednisolone.Illicit, Vet Approved
BortezomibThe risk or severity of adverse effects can be increased when Prednisolone is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Prednisolone can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Prednisolone.Approved
Brefeldin AThe serum concentration of Prednisolone can be increased when it is combined with Brefeldin A.Experimental
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Brentuximab vedotin.Approved, Investigational
BriakinumabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Briakinumab.Investigational
BrodalumabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Brodalumab.Approved, Investigational
BromfenacThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Bromfenac.Approved
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Prednisolone.Approved, Investigational
BudesonideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Budesonide.Approved
BufexamacThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Bufexamac.Approved, Experimental
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Prednisolone.Investigational, Withdrawn
BumadizoneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Bumadizone.Experimental
BumetanideThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Bumetanide.Approved
BuprenorphineThe serum concentration of Prednisolone can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Prednisolone can be increased when it is combined with Buspirone.Approved, Investigational
BusulfanThe risk or severity of adverse effects can be increased when Busulfan is combined with Prednisolone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Prednisolone is combined with Cabazitaxel.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Prednisolone.Approved
CaffeineThe serum concentration of Prednisolone can be increased when it is combined with Caffeine.Approved
CalcidiolThe therapeutic efficacy of Calcidiol can be decreased when used in combination with Prednisolone.Approved, Nutraceutical
CalcipotriolThe therapeutic efficacy of Calcipotriol can be decreased when used in combination with Prednisolone.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prednisolone.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Prednisolone can be decreased when combined with Calcium Carbonate.Approved, Investigational
Calcium silicateThe bioavailability of Prednisolone can be decreased when combined with Calcium silicate.Experimental
CalusteroneThe risk or severity of edema formation can be increased when Calusterone is combined with Prednisolone.Experimental, Illicit
CanagliflozinThe serum concentration of Prednisolone can be increased when it is combined with Canagliflozin.Approved
CanakinumabThe risk or severity of adverse effects can be increased when Canakinumab is combined with Prednisolone.Approved, Investigational
CapecitabineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Capecitabine.Approved, Investigational
Capromab pendetidePrednisolone may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CaptoprilThe serum concentration of Prednisolone can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Prednisolone can be decreased when it is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Prednisolone.Experimental, Investigational
CarbimazoleThe serum concentration of Prednisolone can be decreased when it is combined with Carbimazole.Approved, Investigational
CarboplatinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Carboplatin.Approved
CarbutamideThe therapeutic efficacy of Carbutamide can be decreased when used in combination with Prednisolone.Experimental
CarfilzomibThe risk or severity of adverse effects can be increased when Prednisolone is combined with Carfilzomib.Approved, Investigational
CarmegliptinThe therapeutic efficacy of Carmegliptin can be decreased when used in combination with Prednisolone.Investigational
CarmustineThe risk or severity of adverse effects can be increased when Carmustine is combined with Prednisolone.Approved, Investigational
CarprofenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Prednisolone can be increased when it is combined with Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Castanospermine.Experimental
CefoperazoneThe serum concentration of Prednisolone can be increased when it is combined with Cefoperazone.Approved, Investigational
CeftriaxoneThe serum concentration of Prednisolone can be increased when it is combined with Ceftriaxone.Approved
CelecoxibThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Prednisolone can be increased when it is combined with Ceritinib.Approved
Certolizumab pegolThe risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Prednisolone.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Chlorambucil is combined with Prednisolone.Approved
ChloramphenicolThe risk or severity of adverse effects can be increased when Prednisolone is combined with Chloramphenicol.Approved, Vet Approved
ChlormadinoneThe serum concentration of Prednisolone can be increased when it is combined with Chlormadinone.Experimental
ChloroformThe serum concentration of Prednisolone can be increased when it is combined with Chloroform.Vet Approved
ChlorothiazidePrednisolone may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorpromazineThe serum concentration of Prednisolone can be increased when it is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Prednisolone.Approved, Investigational
ChlorprothixeneThe serum concentration of Prednisolone can be increased when it is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorthalidonePrednisolone may increase the hypokalemic activities of Chlorthalidone.Approved
CholecalciferolThe therapeutic efficacy of Cholecalciferol can be decreased when used in combination with Prednisolone.Approved, Nutraceutical
Choline magnesium trisalicylateThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ciclesonide.Approved, Investigational
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Prednisolone.Experimental
CimicoxibThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Cimicoxib.Investigational
CinoxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Ciprofloxacin.Approved, Investigational
CisatracuriumThe risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Prednisolone.Approved
CisplatinThe risk or severity of adverse effects can be increased when Cisplatin is combined with Prednisolone.Approved
CladribineThe risk or severity of adverse effects can be increased when Cladribine is combined with Prednisolone.Approved, Investigational
ClarithromycinThe serum concentration of Prednisolone can be increased when it is combined with Clarithromycin.Approved
ClenbuterolThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Prednisolone is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Clocortolone.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Prednisolone.Approved, Investigational
ClofazimineThe serum concentration of Prednisolone can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Prednisolone can be increased when it is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Clonixin.Approved
CloprednolThe risk or severity of adverse effects can be increased when Prednisolone is combined with Cloprednol.Experimental
ClostebolThe risk or severity of edema formation can be increased when Clostebol is combined with Prednisolone.Experimental, Illicit
Clostridium tetani toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Prednisolone.Approved
ClotrimazoleThe serum concentration of Prednisolone can be increased when it is combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Prednisolone can be increased when it is combined with Cobicistat.Approved
ColchicineThe serum concentration of Prednisolone can be increased when it is combined with Colchicine.Approved
Concanamycin AThe serum concentration of Prednisolone can be increased when it is combined with Concanamycin A.Experimental
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Prednisolone.Approved, Investigational
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Prednisolone.Approved
CorticotropinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Cortisone acetate.Approved, Investigational
CortivazolThe risk or severity of adverse effects can be increased when Prednisolone is combined with Cortivazol.Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Prednisolone.Approved
CoumaphosThe therapeutic efficacy of Coumaphos can be decreased when used in combination with Prednisolone.Vet Approved
CrizotinibThe serum concentration of Prednisolone can be increased when it is combined with Crizotinib.Approved
CurcuminThe serum concentration of Prednisolone can be increased when it is combined with Curcumin.Approved, Investigational
CyclopenthiazidePrednisolone may increase the hypokalemic activities of Cyclopenthiazide.Experimental
CyclophosphamideThe risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Prednisolone.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Prednisolone.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of adverse effects can be increased when Cytarabine is combined with Prednisolone.Approved, Investigational
DabrafenibThe serum concentration of Prednisolone can be decreased when it is combined with Dabrafenib.Approved, Investigational
DacarbazineThe risk or severity of adverse effects can be increased when Dacarbazine is combined with Prednisolone.Approved, Investigational
DaclatasvirThe serum concentration of Prednisolone can be increased when it is combined with Daclatasvir.Approved, Investigational
DaclizumabThe risk or severity of adverse effects can be increased when Daclizumab is combined with Prednisolone.Investigational, Withdrawn
DactinomycinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Dactinomycin.Approved, Investigational
DanazolThe risk or severity of fluid retention can be increased when Prednisolone is combined with Danazol.Approved
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Prednisolone.Approved
DarunavirThe serum concentration of Prednisolone can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Prednisolone can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Daunorubicin is combined with Prednisolone.Approved
DecamethoniumThe risk or severity of myopathy and weakness can be increased when Decamethonium is combined with Prednisolone.Approved
DecitabineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Prednisolone can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Prednisolone is combined with Deflazacort.Approved, Investigational
DelavirdineThe serum concentration of Prednisolone can be increased when it is combined with Delavirdine.Approved
DemecariumThe therapeutic efficacy of Demecarium can be decreased when used in combination with Prednisolone.Approved
DenosumabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Denosumab.Approved
DeoxyspergualinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Deoxyspergualin.Investigational
DersalazineThe risk or severity of adverse effects can be increased when Dersalazine is combined with Prednisolone.Investigational
DesipramineThe serum concentration of Prednisolone can be increased when it is combined with Desipramine.Approved, Investigational
DesmethylsertralineThe serum concentration of Prednisolone can be increased when it is combined with Desmethylsertraline.Experimental
DesogestrelThe serum concentration of Prednisolone can be increased when it is combined with Desogestrel.Approved
DesonideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Desoximetasone.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Dexketoprofen.Approved, Investigational
DexniguldipineThe serum concentration of Prednisolone can be increased when it is combined with Dexniguldipine.Experimental
DexrazoxaneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Dexrazoxane.Approved, Withdrawn
DexverapamilThe serum concentration of Prednisolone can be increased when it is combined with Dexverapamil.Experimental
DichlorvosThe therapeutic efficacy of Dichlorvos can be decreased when used in combination with Prednisolone.Vet Approved
DiclofenacThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Diclofenac.Approved, Vet Approved
DienogestThe risk or severity of edema formation can be increased when Dienogest is combined with Prednisolone.Approved
Diethyl etherThe serum concentration of Prednisolone can be increased when it is combined with Diethyl ether.Experimental
DifenpiramideThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Diflorasone.Approved
DifloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Difloxacin.Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednisolone.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Difluprednate.Approved
DihydroergocornineThe metabolism of Dihydroergocornine can be decreased when combined with Prednisolone.Approved
DihydroergocristineThe metabolism of Dihydroergocristine can be decreased when combined with Prednisolone.Approved, Experimental
DihydroergocryptineThe metabolism of Dihydroergocryptine can be decreased when combined with Prednisolone.Experimental
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Prednisolone.Approved, Investigational
DihydrotachysterolThe therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Prednisolone.Approved
DiltiazemThe serum concentration of Prednisolone can be increased when it is combined with Diltiazem.Approved, Investigational
Dimethyl fumarateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Dimethyl fumarate.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Dinutuximab.Approved, Investigational
DipivefrinThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Dipivefrin.Approved
DipyridamoleThe serum concentration of Prednisolone can be increased when it is combined with Dipyridamole.Approved
DisopyramideThe therapeutic efficacy of Disopyramide can be decreased when used in combination with Prednisolone.Approved
DistigmineThe therapeutic efficacy of Distigmine can be decreased when used in combination with Prednisolone.Experimental
DobutamineThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Dobutamine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Prednisolone is combined with Docetaxel.Approved, Investigational
DofequidarThe serum concentration of Prednisolone can be increased when it is combined with Dofequidar.Experimental, Investigational
DonepezilThe therapeutic efficacy of Donepezil can be decreased when used in combination with Prednisolone.Approved
DovitinibThe serum concentration of Prednisolone can be increased when it is combined with Dovitinib.Investigational
DoxacuriumThe risk or severity of myopathy and weakness can be increased when Doxacurium is combined with Prednisolone.Approved
DoxazosinThe serum concentration of Prednisolone can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Prednisolone can be increased when it is combined with Doxepin.Approved, Investigational
DoxercalciferolThe therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Prednisolone.Approved
DoxifluridineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Doxifluridine.Investigational
DoxofyllineThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Doxofylline.Approved, Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe serum concentration of Prednisolone can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Prednisolone can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Prednisolone can be increased when it is combined with Dronedarone.Approved
DrospirenoneThe serum concentration of Prednisolone can be increased when it is combined with Drospirenone.Approved
DroxicamThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Droxicam.Withdrawn
DroxidopaThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Droxidopa.Approved, Investigational
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Prednisolone.Approved, Investigational
DuloxetineThe serum concentration of Prednisolone can be increased when it is combined with Duloxetine.Approved
DutogliptinThe therapeutic efficacy of Dutogliptin can be decreased when used in combination with Prednisolone.Investigational
EchothiophateThe therapeutic efficacy of Echothiophate can be decreased when used in combination with Prednisolone.Approved
EconazoleThe serum concentration of Prednisolone can be increased when it is combined with Econazole.Approved
EculizumabThe risk or severity of adverse effects can be increased when Eculizumab is combined with Prednisolone.Approved, Investigational
EdrophoniumThe therapeutic efficacy of Edrophonium can be decreased when used in combination with Prednisolone.Approved
EfalizumabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Efalizumab.Approved, Investigational
EfavirenzThe serum concentration of Prednisolone can be increased when it is combined with Efavirenz.Approved, Investigational
ElacridarThe serum concentration of Prednisolone can be increased when it is combined with Elacridar.Investigational
EldecalcitolThe therapeutic efficacy of Eldecalcitol can be decreased when used in combination with Prednisolone.Investigational
ElocalcitolThe therapeutic efficacy of Elocalcitol can be decreased when used in combination with Prednisolone.Investigational
EmopamilThe serum concentration of Prednisolone can be increased when it is combined with Emopamil.Experimental
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Prednisolone.Approved
EnasidenibThe serum concentration of Prednisolone can be increased when it is combined with Enasidenib.Approved, Investigational
EnglitazoneThe therapeutic efficacy of Englitazone can be decreased when used in combination with Prednisolone.Experimental
EnoxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Enoxacin.Approved, Investigational
EnzalutamideThe serum concentration of Prednisolone can be decreased when it is combined with Enzalutamide.Approved
EphedraThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpinephrineThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Epinephrine.Approved, Vet Approved
EpirizoleThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Epirizole.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Epirubicin is combined with Prednisolone.Approved
EpitizidePrednisolone may increase the hypokalemic activities of Epitizide.Experimental
ErgocalciferolThe therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Prednisolone.Approved, Nutraceutical
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be decreased when combined with Prednisolone.Approved
ErgonovineThe metabolism of Ergonovine can be decreased when combined with Prednisolone.Approved
ErgotamineThe metabolism of Ergotamine can be decreased when combined with Prednisolone.Approved
EribulinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Eribulin.Approved, Investigational
ErlotinibThe serum concentration of Prednisolone can be increased when it is combined with Erlotinib.Approved, Investigational
ErythromycinThe serum concentration of Prednisolone can be increased when it is combined with Erythromycin.Approved, Investigational, Vet Approved
EsomeprazoleThe serum concentration of Prednisolone can be increased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Prednisolone can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstramustineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Estramustine.Approved, Investigational
Etacrynic acidThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Etacrynic acid.Approved, Investigational
EtafedrineThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Etafedrine.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Prednisolone.Approved, Investigational
EthenzamideThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Ethenzamide.Experimental
Ethinyl EstradiolThe serum concentration of Prednisolone can be increased when it is combined with Ethinyl Estradiol.Approved
EthynodiolThe serum concentration of Prednisolone can be increased when it is combined with Ethynodiol.Experimental
Ethynodiol diacetateThe serum concentration of Prednisolone can be increased when it is combined with Ethynodiol diacetate.Approved
EtodolacThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Etofenamate.Approved, Investigational
EtonogestrelThe serum concentration of Prednisolone can be increased when it is combined with Etonogestrel.Approved, Investigational
EtoposideThe risk or severity of adverse effects can be increased when Etoposide is combined with Prednisolone.Approved
EtoricoxibThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Etoricoxib.Approved, Investigational
EtravirineThe serum concentration of Prednisolone can be decreased when it is combined with Etravirine.Approved
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Prednisolone.Approved
EvogliptinThe therapeutic efficacy of Evogliptin can be decreased when used in combination with Prednisolone.Investigational
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Prednisolone.Approved, Investigational
FelbinacThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Felbinac.Experimental
FelodipineThe serum concentration of Prednisolone can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Fenbufen.Approved
FenofibrateThe serum concentration of Prednisolone can be increased when it is combined with Fenofibrate.Approved
FenoprofenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Fenoprofen.Approved
FenoterolThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Fenoterol.Approved, Investigational
FentanylThe serum concentration of Prednisolone can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Fenthion can be decreased when used in combination with Prednisolone.Vet Approved
FentiazacThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Feprazone.Experimental
FingolimodThe risk or severity of adverse effects can be increased when Fingolimod is combined with Prednisolone.Approved, Investigational
FirocoxibThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Firocoxib.Experimental, Vet Approved
FleroxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Floctafenine.Approved, Withdrawn
FloxuridineThe risk or severity of adverse effects can be increased when Floxuridine is combined with Prednisolone.Approved
FluasteroneThe risk or severity of edema formation can be increased when Fluasterone is combined with Prednisolone.Investigational
FlucloroloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fluclorolone.Experimental
FluconazoleThe serum concentration of Prednisolone can be increased when it is combined with Fluconazole.Approved, Investigational
FlucytosineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Flucytosine.Approved, Investigational
FludarabineThe risk or severity of adverse effects can be increased when Fludarabine is combined with Prednisolone.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Prednisolone.Approved, Investigational
FlumequineThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fluocinonide.Approved, Investigational
FluocortinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fluocortin.Experimental
FluocortoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fluorometholone.Approved, Investigational
FluorouracilThe risk or severity of adverse effects can be increased when Fluorouracil is combined with Prednisolone.Approved
FluoxetineThe serum concentration of Prednisolone can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluoxymesteroneThe risk or severity of fluid retention can be increased when Prednisolone is combined with Fluoxymesterone.Approved, Illicit
FlupentixolThe serum concentration of Prednisolone can be increased when it is combined with Flupentixol.Approved, Investigational, Withdrawn
FluperoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fluperolone.Experimental
FluphenazineThe serum concentration of Prednisolone can be increased when it is combined with Fluphenazine.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fluprednisolone.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Flurandrenolide.Approved
FlurazepamThe serum concentration of Prednisolone can be increased when it is combined with Flurazepam.Approved, Illicit, Investigational
FlurbiprofenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fluticasone propionate.Approved
FluvoxamineThe serum concentration of Prednisolone can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of edema formation can be increased when Formestane is combined with Prednisolone.Approved, Investigational, Withdrawn
FormocortalThe risk or severity of adverse effects can be increased when Prednisolone is combined with Formocortal.Experimental
FormoterolThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Formoterol.Approved, Investigational
FosamprenavirThe metabolism of Prednisolone can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Prednisolone can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Prednisolone can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FurosemideThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Prednisolone can be increased when it is combined with Fusidic Acid.Approved, Investigational
G17DTThe therapeutic efficacy of G17DT can be decreased when used in combination with Prednisolone.Investigational
GalantamineThe therapeutic efficacy of Galantamine can be decreased when used in combination with Prednisolone.Approved
GallamineThe risk or severity of myopathy and weakness can be increased when Gallamine is combined with Prednisolone.Experimental
Gallamine TriethiodideThe risk or severity of myopathy and weakness can be increased when Gallamine Triethiodide is combined with Prednisolone.Approved
Gallium nitrateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Gallium nitrate.Approved, Investigational
GallopamilThe serum concentration of Prednisolone can be increased when it is combined with Gallopamil.Investigational
GarenoxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Garenoxacin.Investigational
GatifloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Gatifloxacin.Approved, Investigational
GefitinibThe serum concentration of Prednisolone can be increased when it is combined with Gefitinib.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Gemcitabine is combined with Prednisolone.Approved
GemifloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Gemifloxacin.Approved, Investigational
GemigliptinThe therapeutic efficacy of Gemigliptin can be decreased when used in combination with Prednisolone.Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednisolone.Approved, Investigational
GenisteinThe serum concentration of Prednisolone can be increased when it is combined with Genistein.Investigational
GestodeneThe serum concentration of Prednisolone can be increased when it is combined with Gestodene.Approved, Investigational
GI-5005The therapeutic efficacy of GI-5005 can be decreased when used in combination with Prednisolone.Investigational
Ginkgo bilobaThe therapeutic efficacy of Ginkgo biloba can be decreased when used in combination with Prednisolone.Approved, Investigational, Nutraceutical
GlatiramerThe risk or severity of adverse effects can be increased when Glatiramer is combined with Prednisolone.Approved, Investigational
GlecaprevirThe serum concentration of Prednisolone can be increased when it is combined with Glecaprevir.Approved, Investigational
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Prednisolone.Investigational, Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Prednisolone.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Prednisolone.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Prednisolone.Approved, Investigational
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Prednisolone.Approved, Investigational
GlisoxepideThe therapeutic efficacy of Glisoxepide can be decreased when used in combination with Prednisolone.Investigational
GLPG-0492The risk or severity of fluid retention can be increased when Prednisolone is combined with GLPG-0492.Investigational
GlyburideThe serum concentration of Prednisolone can be increased when it is combined with Glyburide.Approved
GlycerinThe serum concentration of Prednisolone can be increased when it is combined with Glycerin.Approved, Investigational
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Prednisolone.Approved
GlycodiazineThe therapeutic efficacy of Glycodiazine can be decreased when used in combination with Prednisolone.Approved, Investigational
GolimumabThe risk or severity of adverse effects can be increased when Golimumab is combined with Prednisolone.Approved
GosogliptinThe therapeutic efficacy of Gosogliptin can be decreased when used in combination with Prednisolone.Investigational
Gramicidin DThe serum concentration of Prednisolone can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Prednisolone.Experimental
Guar gumThe therapeutic efficacy of Guar gum can be decreased when used in combination with Prednisolone.Experimental
GusperimusThe risk or severity of adverse effects can be increased when Gusperimus is combined with Prednisolone.Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Halcinonide.Approved, Investigational, Withdrawn
HalometasoneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Halometasone.Experimental
Hepatitis A VaccineThe therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Prednisolone.Approved
Hepatitis B Vaccine (Recombinant)The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Prednisolone.Approved, Withdrawn
HexoprenalineThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Hexoprenaline.Approved, Withdrawn
HM-30181The serum concentration of Prednisolone can be increased when it is combined with HM-30181.Experimental
Human rabies virus immune globulinThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Prednisolone.Approved
Huperzine AThe therapeutic efficacy of Huperzine A can be decreased when used in combination with Prednisolone.Approved, Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednisolone.Approved, Investigational
HycanthoneThe serum concentration of Prednisolone can be increased when it is combined with Hycanthone.Approved, Investigational
HydrochlorothiazidePrednisolone may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Prednisolone.Approved, Illicit
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Prednisolone.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Hydrocortisone aceponate.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Hydrocortisone butyrate.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Hydrocortisone probutate.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Hydrocortisone succinate.Approved
Hydrocortisone valerateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Hydrocortisone valerate.Approved, Vet Approved
HydroflumethiazidePrednisolone may increase the hypokalemic activities of Hydroflumethiazide.Approved, Investigational
HydrotalciteThe bioavailability of Prednisolone can be decreased when combined with Hydrotalcite.Approved, Experimental, Investigational
HydroxychloroquineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Hydroxychloroquine.Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Prednisolone is combined with Hydroxyurea.Approved
HypericinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Hypericin.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisolone.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Prednisolone.Approved
IbuprofenThe serum concentration of Prednisolone can be increased when it is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Ibuproxam.Withdrawn
IcosapentThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Icosapent.Approved, Nutraceutical
IdarubicinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Idarubicin.Approved
IdelalisibThe serum concentration of Prednisolone can be increased when it is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ifosfamide.Approved
ImatinibThe risk or severity of adverse effects can be increased when Imatinib is combined with Prednisolone.Approved
Imidazole salicylateThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Imidazole salicylate.Experimental
ImiquimodThe risk or severity of adverse effects can be increased when Imiquimod is combined with Prednisolone.Approved, Investigational
IndacaterolThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Indacaterol.Approved
IndapamidePrednisolone may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe serum concentration of Prednisolone can be increased when it is combined with Indinavir.Approved
IndobufenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Indobufen.Investigational
IndomethacinThe serum concentration of Prednisolone can be increased when it is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Indoprofen.Withdrawn
InecalcitolThe therapeutic efficacy of Inecalcitol can be decreased when used in combination with Prednisolone.Experimental, Investigational
InfliximabThe risk or severity of adverse effects can be increased when Infliximab is combined with Prednisolone.Approved
INGN 225The therapeutic efficacy of INGN 225 can be decreased when used in combination with Prednisolone.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Prednisolone.Approved
Insulin BeefThe therapeutic efficacy of Insulin Beef can be decreased when used in combination with Prednisolone.Approved
Insulin DegludecThe therapeutic efficacy of Insulin Degludec can be decreased when used in combination with Prednisolone.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Prednisolone.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Prednisolone.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Prednisolone.Approved
Insulin HumanThe therapeutic efficacy of Insulin Human can be decreased when used in combination with Prednisolone.Approved, Investigational
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Prednisolone.Approved
Insulin peglisproThe therapeutic efficacy of Insulin peglispro can be decreased when used in combination with Prednisolone.Investigational
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Prednisolone.Approved
Interferon alfa-n3The risk or severity of adverse effects can be increased when Prednisolone is combined with Interferon alfa-n3.Approved, Investigational
Interferon alfacon-1The risk or severity of adverse effects can be increased when Prednisolone is combined with Interferon alfacon-1.Approved, Investigational
IpidacrineThe therapeutic efficacy of Ipidacrine can be decreased when used in combination with Prednisolone.Experimental
IrinotecanThe risk or severity of adverse effects can be increased when Irinotecan is combined with Prednisolone.Approved, Investigational
IsavuconazoleThe serum concentration of Prednisolone can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of Prednisolone can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsoetarineThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Isoetarine.Approved
IsoflurophateThe therapeutic efficacy of Isoflurophate can be decreased when used in combination with Prednisolone.Approved, Investigational, Withdrawn
IsoniazidThe therapeutic efficacy of Isoniazid can be decreased when used in combination with Prednisolone.Approved, Investigational
IsoprenalineThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Isoprenaline.Approved, Investigational
IsoxicamThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Isoxicam.Withdrawn
IsradipineThe serum concentration of Prednisolone can be increased when it is combined with Isradipine.Approved, Investigational
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Prednisolone.Investigational
ItraconazoleThe serum concentration of Prednisolone can be increased when it is combined with Itraconazole.Approved, Investigational
IvermectinThe serum concentration of Prednisolone can be increased when it is combined with Ivermectin.Approved, Investigational, Vet Approved
IvosidenibThe serum concentration of Prednisolone can be increased when it is combined with Ivosidenib.Approved, Investigational
IxabepiloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ixabepilone.Approved, Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Prednisolone.Approved
KebuzoneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Kebuzone.Experimental
KetoconazoleThe serum concentration of Prednisolone can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Ketorolac.Approved
KRP-104The therapeutic efficacy of KRP-104 can be decreased when used in combination with Prednisolone.Investigational
L-PhenylalanineThe risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Prednisolone.Approved, Investigational, Nutraceutical
LaniquidarThe serum concentration of Prednisolone can be increased when it is combined with Laniquidar.Investigational
LansoprazoleThe serum concentration of Prednisolone can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Prednisolone can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Prednisolone can be increased when it is combined with Ledipasvir.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Prednisolone.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Lenalidomide is combined with Prednisolone.Approved
LetermovirThe serum concentration of Prednisolone can be increased when it is combined with Letermovir.Approved, Investigational
LevofloxacinThe serum concentration of Prednisolone can be increased when it is combined with Levofloxacin.Approved, Investigational
LevonorgestrelThe serum concentration of Prednisolone can be increased when it is combined with Levonorgestrel.Approved, Investigational
LevosalbutamolThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Levosalbutamol.Approved, Investigational
LidocaineThe serum concentration of Prednisolone can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Prednisolone can be increased when it is combined with Linagliptin.Approved
LinezolidThe risk or severity of adverse effects can be increased when Prednisolone is combined with Linezolid.Approved, Investigational
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Prednisolone.Approved
LisurideThe metabolism of Lisuride can be decreased when combined with Prednisolone.Approved, Investigational
LixisenatideThe therapeutic efficacy of Lixisenatide can be decreased when used in combination with Prednisolone.Approved
LobeglitazoneThe therapeutic efficacy of Lobeglitazone can be decreased when used in combination with Prednisolone.Approved, Investigational
LomefloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Lomefloxacin.Approved, Investigational
LomerizineThe serum concentration of Prednisolone can be increased when it is combined with Lomerizine.Experimental
LomitapideThe serum concentration of Prednisolone can be increased when it is combined with Lomitapide.Approved, Investigational
LomustineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Lomustine.Approved, Investigational
LonafarnibThe serum concentration of Prednisolone can be increased when it is combined with Lonafarnib.Investigational
LonazolacThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Lonazolac.Experimental
LoperamideThe serum concentration of Prednisolone can be increased when it is combined with Loperamide.Approved
LopinavirThe serum concentration of Prednisolone can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Prednisolone can be increased when it is combined with Loratadine.Approved, Investigational
LornoxicamThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Prednisolone can be increased when it is combined with Lorpiprazole.Approved
LosartanThe serum concentration of Prednisolone can be increased when it is combined with Losartan.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Prednisolone is combined with Loteprednol.Approved
LovastatinThe serum concentration of Prednisolone can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineThe serum concentration of Prednisolone can be increased when it is combined with Loxapine.Approved
LoxoprofenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Loxoprofen.Approved, Investigational
LuliconazoleThe serum concentration of Prednisolone can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Prednisolone can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Lumiracoxib.Approved, Investigational
LusutrombopagThe serum concentration of Prednisolone can be increased when it is combined with Lusutrombopag.Approved, Investigational
LynestrenolThe serum concentration of Prednisolone can be increased when it is combined with Lynestrenol.Approved, Investigational
Lysergic Acid DiethylamideThe metabolism of Lysergic Acid Diethylamide can be decreased when combined with Prednisolone.Illicit, Investigational, Withdrawn
MagaldrateThe bioavailability of Prednisolone can be decreased when combined with Magaldrate.Approved, Withdrawn
Magnesium carbonateThe bioavailability of Prednisolone can be decreased when combined with Magnesium carbonate.Approved, Investigational
Magnesium hydroxideThe bioavailability of Prednisolone can be decreased when combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe bioavailability of Prednisolone can be decreased when combined with Magnesium oxide.Approved
Magnesium peroxideThe bioavailability of Prednisolone can be decreased when combined with Magnesium peroxide.Experimental
Magnesium salicylateThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Magnesium salicylate.Approved
Magnesium silicateThe bioavailability of Prednisolone can be decreased when combined with Magnesium silicate.Approved
Magnesium TrisilicateThe bioavailability of Prednisolone can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe therapeutic efficacy of Malathion can be decreased when used in combination with Prednisolone.Approved, Investigational
MaxacalcitolThe therapeutic efficacy of Maxacalcitol can be decreased when used in combination with Prednisolone.Approved, Investigational
MecaserminThe therapeutic efficacy of Mecasermin can be decreased when used in combination with Prednisolone.Approved, Investigational
MechlorethamineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Mechlorethamine.Approved, Investigational
Meclofenamic acidThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Meclofenamic acid.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Prednisolone can be increased when it is combined with Medroxyprogesterone acetate.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Mefenamic acid.Approved
MefloquineThe serum concentration of Prednisolone can be increased when it is combined with Mefloquine.Approved, Investigational
Megestrol acetateThe serum concentration of Prednisolone can be increased when it is combined with Megestrol acetate.Approved, Investigational, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Prednisolone is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Meloxicam.Approved, Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Melphalan is combined with Prednisolone.Approved
MepolizumabThe risk or severity of adverse effects can be increased when Mepolizumab is combined with Prednisolone.Approved, Investigational
MeprednisoneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Meprednisone.Approved, Investigational
MercaptopurineThe risk or severity of adverse effects can be increased when Mercaptopurine is combined with Prednisolone.Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prednisolone.Approved
MesteroloneThe risk or severity of edema formation can be increased when Mesterolone is combined with Prednisolone.Experimental
MetahexamideThe therapeutic efficacy of Metahexamide can be decreased when used in combination with Prednisolone.Experimental
MetamizoleThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Metamizole.Approved, Investigational, Withdrawn
MetenoloneThe risk or severity of edema formation can be increased when Metenolone is combined with Prednisolone.Experimental
MetergolineThe metabolism of Metergoline can be decreased when combined with Prednisolone.Experimental
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone.Approved
MethadoneThe serum concentration of Prednisolone can be increased when it is combined with Methadone.Approved
Methanesulfonyl FluorideThe therapeutic efficacy of Methanesulfonyl Fluoride can be decreased when used in combination with Prednisolone.Investigational
MethimazoleThe serum concentration of Prednisolone can be decreased when it is combined with Methimazole.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Prednisolone.Approved
MethyclothiazidePrednisolone may increase the hypokalemic activities of Methyclothiazide.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Methyl salicylate is combined with Prednisolone.Approved, Vet Approved
MethylergometrineThe metabolism of Methylergometrine can be decreased when combined with Prednisolone.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneThe risk or severity of edema formation can be increased when Methyltestosterone is combined with Prednisolone.Approved
MethysergideThe metabolism of Methysergide can be decreased when combined with Prednisolone.Approved
MetoclopramideThe therapeutic efficacy of Metoclopramide can be decreased when used in combination with Prednisolone.Approved, Investigational
MetocurineThe risk or severity of myopathy and weakness can be increased when Metocurine is combined with Prednisolone.Approved
Metocurine IodideThe risk or severity of myopathy and weakness can be increased when Metocurine Iodide is combined with Prednisolone.Approved, Withdrawn
MetolazonePrednisolone may increase the hypokalemic activities of Metolazone.Approved
MetronidazoleThe serum concentration of Prednisolone can be increased when it is combined with Metronidazole.Approved
MibefradilThe serum concentration of Prednisolone can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiboleroneThe risk or severity of edema formation can be increased when Mibolerone is combined with Prednisolone.Vet Approved
MiconazoleThe serum concentration of Prednisolone can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Prednisolone can be increased when it is combined with Midazolam.Approved, Illicit
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Prednisolone.Approved, Experimental
MifepristoneThe serum concentration of Prednisolone can be increased when it is combined with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Prednisolone.Approved
MinaprineThe therapeutic efficacy of Minaprine can be decreased when used in combination with Prednisolone.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Prednisolone.Approved, Investigational
MitomycinThe risk or severity of adverse effects can be increased when Mitomycin is combined with Prednisolone.Approved
MitotaneThe serum concentration of Prednisolone can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Mitoxantrone.Approved, Investigational
MivacuriumThe risk or severity of myopathy and weakness can be increased when Mivacurium is combined with Prednisolone.Approved
MizoribineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Mizoribine.Investigational
ModafinilThe serum concentration of Prednisolone can be decreased when it is combined with Modafinil.Approved, Investigational
MofebutazoneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Mometasone.Approved, Vet Approved
Mometasone furoateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Mometasone furoate.Approved, Vet Approved
MonensinThe serum concentration of Prednisolone can be increased when it is combined with Monensin.Vet Approved
MorniflumateThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Morniflumate.Approved
MoxifloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Moxifloxacin.Approved, Investigational
MuromonabThe risk or severity of adverse effects can be increased when Muromonab is combined with Prednisolone.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prednisolone.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednisolone.Approved
NabumetoneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Nabumetone.Approved
NafcillinThe serum concentration of Prednisolone can be decreased when it is combined with Nafcillin.Approved, Investigational
Nalidixic AcidThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Nalidixic Acid.Approved, Investigational
NaloxoneThe serum concentration of Prednisolone can be increased when it is combined with Naloxone.Approved, Vet Approved
NandroloneThe risk or severity of edema formation can be increased when Nandrolone is combined with Prednisolone.Experimental, Investigational
Nandrolone decanoateThe risk or severity of edema formation can be increased when Nandrolone decanoate is combined with Prednisolone.Approved, Illicit
Nandrolone phenpropionateThe risk or severity of edema formation can be increased when Nandrolone phenpropionate is combined with Prednisolone.Approved, Illicit, Investigational
NaproxenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Naproxen.Approved, Vet Approved
NatalizumabThe risk or severity of adverse effects can be increased when Natalizumab is combined with Prednisolone.Approved, Investigational
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Prednisolone.Approved, Investigational
NBI-6024The therapeutic efficacy of NBI-6024 can be decreased when used in combination with Prednisolone.Investigational
NefazodoneThe serum concentration of Prednisolone can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Nelarabine.Approved, Investigational
NelfinavirThe serum concentration of Prednisolone can be increased when it is combined with Nelfinavir.Approved
NemonoxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Nemonoxacin.Investigational
NeosaxitoxinThe risk or severity of myopathy and weakness can be increased when Neosaxitoxin is combined with Prednisolone.Investigational
NeostigmineThe therapeutic efficacy of Neostigmine can be decreased when used in combination with Prednisolone.Approved, Vet Approved
NepafenacThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Nepafenac.Approved, Investigational
NeratinibThe serum concentration of Prednisolone can be increased when it is combined with Neratinib.Approved, Investigational
NetoglitazoneThe therapeutic efficacy of Netoglitazone can be decreased when used in combination with Prednisolone.Experimental
NetupitantThe serum concentration of Prednisolone can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Prednisolone can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Prednisolone can be increased when it is combined with Nicardipine.Approved, Investigational
NicergolineThe metabolism of Nicergoline can be decreased when combined with Prednisolone.Approved, Investigational
NicorandilThe risk or severity of ulceration can be increased when Prednisolone is combined with Nicorandil.Approved, Investigational
NifenazoneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Niflumic Acid.Approved
NigericinThe serum concentration of Prednisolone can be increased when it is combined with Nigericin.Experimental
NiguldipineThe serum concentration of Prednisolone can be increased when it is combined with Niguldipine.Experimental
NilotinibThe serum concentration of Prednisolone can be increased when it is combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Prednisolone.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Prednisolone.Approved
NisoldipineThe serum concentration of Prednisolone can be increased when it is combined with Nisoldipine.Approved
NitrendipineThe serum concentration of Prednisolone can be increased when it is combined with Nitrendipine.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Prednisolone.Investigational
NN344The therapeutic efficacy of NN344 can be decreased when used in combination with Prednisolone.Investigational
NomegestrolThe serum concentration of Prednisolone can be increased when it is combined with Nomegestrol.Approved
NorelgestrominThe serum concentration of Prednisolone can be increased when it is combined with Norelgestromin.Approved, Investigational
NorepinephrineThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Norepinephrine.Approved
NorethisteroneThe serum concentration of Prednisolone can be increased when it is combined with Norethisterone.Approved
NorfloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Norfloxacin.Approved
NorgestimateThe serum concentration of Prednisolone can be increased when it is combined with Norgestimate.Approved, Investigational
NorgestrelThe serum concentration of Prednisolone can be increased when it is combined with Norgestrel.Approved
NorgestrienoneThe serum concentration of Prednisolone can be increased when it is combined with Norgestrienone.Experimental
NS-398The risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with NS-398.Experimental
ObinutuzumabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Obinutuzumab.Approved, Investigational
OcrelizumabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ocrelizumab.Approved, Investigational
OfloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Ofloxacin.Approved
OlaparibThe risk or severity of adverse effects can be increased when Prednisolone is combined with Olaparib.Approved
OlodaterolThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Olodaterol.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Prednisolone.Approved
OmarigliptinThe therapeutic efficacy of Omarigliptin can be decreased when used in combination with Prednisolone.Investigational
OmeprazoleThe serum concentration of Prednisolone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
ONT-093The serum concentration of Prednisolone can be increased when it is combined with ONT-093.Investigational
OrbifloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Orbifloxacin.Vet Approved
OrciprenalineThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Orciprenaline.Approved
OsimertinibThe serum concentration of Prednisolone can be increased when it is combined with Osimertinib.Approved
OxaliplatinThe risk or severity of adverse effects can be increased when Oxaliplatin is combined with Prednisolone.Approved, Investigational
OxandroloneThe risk or severity of fluid retention can be increased when Prednisolone is combined with Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Oxaprozin.Approved
Oxolinic acidThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Oxolinic acid.Experimental
OxymetholoneThe risk or severity of fluid retention can be increased when Prednisolone is combined with Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Prednisolone is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Prednisolone can be increased when it is combined with Palbociclib.Approved, Investigational
PaliperidoneThe serum concentration of Prednisolone can be increased when it is combined with Paliperidone.Approved
PancuroniumThe risk or severity of myopathy and weakness can be increased when Pancuronium is combined with Prednisolone.Approved
PanobinostatThe risk or severity of adverse effects can be increased when Prednisolone is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Prednisolone can be increased when it is combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Paramethasone.Approved
ParaoxonThe therapeutic efficacy of Paraoxon can be decreased when used in combination with Prednisolone.Experimental
ParecoxibThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Parecoxib.Approved
ParicalcitolThe therapeutic efficacy of Paricalcitol can be decreased when used in combination with Prednisolone.Approved, Investigational
ParitaprevirThe serum concentration of Prednisolone can be increased when it is combined with Paritaprevir.Approved, Investigational
ParoxetineThe serum concentration of Prednisolone can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pazopanib.Approved
PazufloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Pefloxacin.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Pegaspargase is combined with Prednisolone.Approved, Investigational
Peginterferon alfa-2aThe risk or severity of adverse effects can be increased when Prednisolone is combined with Peginterferon alfa-2a.Approved, Investigational
Peginterferon alfa-2bThe risk or severity of adverse effects can be increased when Prednisolone is combined with Peginterferon alfa-2b.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Pemetrexed is combined with Prednisolone.Approved, Investigational
PentamidineThe therapeutic efficacy of Pentamidine can be decreased when used in combination with Prednisolone.Approved, Investigational
PentazocineThe serum concentration of Prednisolone can be increased when it is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe serum concentration of Prednisolone can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PentostatinThe risk or severity of adverse effects can be increased when Pentostatin is combined with Prednisolone.Approved, Investigational
PergolideThe metabolism of Pergolide can be decreased when combined with Prednisolone.Approved, Investigational, Vet Approved, Withdrawn
PethidineThe serum concentration of Prednisolone can be increased when it is combined with Pethidine.Approved
PF-00610355The risk or severity of hypokalemia can be increased when Prednisolone is combined with PF-00610355.Investigational
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Prednisolone.Approved, Investigational, Withdrawn
PhenobarbitalThe serum concentration of Prednisolone can be decreased when it is combined with Phenobarbital.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Prednisolone.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Prednisolone.Approved
PhenylbutazoneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Phenylbutazone.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Prednisolone.Approved, Investigational
PhenylpropanolamineThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Prednisolone can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Physostigmine can be decreased when used in combination with Prednisolone.Approved, Investigational
PibrentasvirThe serum concentration of Prednisolone can be increased when it is combined with Pibrentasvir.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pimecrolimus.Approved, Investigational
PimozideThe serum concentration of Prednisolone can be increased when it is combined with Pimozide.Approved
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Prednisolone.Approved, Investigational
PipecuroniumThe risk or severity of myopathy and weakness can be increased when Pipecuronium is combined with Prednisolone.Approved
Pipemidic acidThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Pipemidic acid.Experimental
PirarubicinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pirarubicin.Investigational
PirbuterolThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Pirbuterol.Approved
PiretanideThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Piretanide.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pirfenidone.Approved, Investigational
Piromidic acidThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Pirprofen.Experimental
PitolisantThe serum concentration of Prednisolone can be decreased when it is combined with Pitolisant.Approved, Investigational
PolythiazidePrednisolone may increase the hypokalemic activities of Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Prednisolone.Approved
PonatinibThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ponatinib.Approved, Investigational
PosaconazoleThe serum concentration of Prednisolone can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pralatrexate.Approved, Investigational
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Prednisolone.Approved, Investigational
PranoprofenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of edema formation can be increased when Prasterone is combined with Prednisolone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of edema formation can be increased when Prasterone sulfate is combined with Prednisolone.Investigational
PrazosinThe serum concentration of Prednisolone can be increased when it is combined with Prazosin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Prednicarbate.Approved, Investigational
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Prednisolone.Approved, Vet Approved
PrednylideneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Prednylidene.Experimental
PrimaquineThe serum concentration of Prednisolone can be increased when it is combined with Primaquine.Approved
PrimidoneThe serum concentration of Prednisolone can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Procarbazine.Approved, Investigational
ProcaterolThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Procaterol.Approved, Investigational
ProgesteroneThe serum concentration of Prednisolone can be increased when it is combined with Progesterone.Approved, Vet Approved
ProglumetacinThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Proglumetacin.Experimental
PromethazineThe serum concentration of Prednisolone can be increased when it is combined with Promethazine.Approved, Investigational
PropacetamolThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Propacetamol.Approved, Investigational
PropafenoneThe serum concentration of Prednisolone can be increased when it is combined with Propafenone.Approved
PropofolThe serum concentration of Prednisolone can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
PropylthiouracilThe risk or severity of adverse effects can be increased when Prednisolone is combined with Propylthiouracil.Approved, Investigational
PropyphenazoneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Proquazone.Experimental
ProtokylolThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Protokylol.Approved, Vet Approved
ProtriptylineThe serum concentration of Prednisolone can be increased when it is combined with Protriptyline.Approved
PrulifloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Prulifloxacin.Investigational
PyrantelThe risk or severity of myopathy and weakness can be increased when Pyrantel is combined with Prednisolone.Approved, Vet Approved
PyridostigmineThe therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Prednisolone.Approved, Investigational
QuercetinThe serum concentration of Prednisolone can be increased when it is combined with Quercetin.Experimental, Investigational
QuinacrineThe serum concentration of Prednisolone can be increased when it is combined with Quinacrine.Approved, Investigational
QuinethazonePrednisolone may increase the hypokalemic activities of Quinethazone.Approved
QuingestanolThe serum concentration of Prednisolone can be increased when it is combined with Quingestanol.Experimental
QuinidineThe serum concentration of Prednisolone can be increased when it is combined with Quinidine.Approved, Investigational
QuinineThe serum concentration of Prednisolone can be decreased when it is combined with Quinine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Prednisolone.Approved, Investigational
RacepinephrineThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Racepinephrine.Approved
RaltitrexedThe risk or severity of adverse effects can be increased when Prednisolone is combined with Raltitrexed.Approved, Investigational
RanitidineThe serum concentration of Prednisolone can be increased when it is combined with Ranitidine.Approved
RapacuroniumThe risk or severity of myopathy and weakness can be increased when Rapacuronium is combined with Prednisolone.Withdrawn
ReboxetineThe serum concentration of Prednisolone can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Prednisolone can be increased when it is combined with Regorafenib.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Prednisolone.Approved, Investigational
ReserpineThe serum concentration of Prednisolone can be increased when it is combined with Reserpine.Approved, Investigational
Reversin 121The serum concentration of Prednisolone can be increased when it is combined with Reversin 121.Experimental
RifampicinThe serum concentration of Prednisolone can be decreased when it is combined with Rifampicin.Approved
RifamycinThe serum concentration of Prednisolone can be decreased when it is combined with Rifamycin.Investigational
RifapentineThe serum concentration of Prednisolone can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Prednisolone can be decreased when it is combined with Rifaximin.Approved, Investigational
RilonaceptThe risk or severity of adverse effects can be increased when Rilonacept is combined with Prednisolone.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Prednisolone.Approved
RimexoloneThe serum concentration of Prednisolone can be decreased when it is combined with Rimexolone.Approved
RindopepimutThe therapeutic efficacy of Rindopepimut can be decreased when used in combination with Prednisolone.Investigational
RisperidoneThe metabolism of Prednisolone can be decreased when combined with Risperidone.Approved, Investigational
RitodrineThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Prednisolone can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Rituximab is combined with Prednisolone.Approved
RivastigmineThe therapeutic efficacy of Rivastigmine can be decreased when used in combination with Prednisolone.Approved, Investigational
RivoglitazoneThe therapeutic efficacy of Rivoglitazone can be decreased when used in combination with Prednisolone.Experimental, Investigational
RobenacoxibThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Robenacoxib.Experimental, Vet Approved
RocuroniumThe risk or severity of myopathy and weakness can be increased when Rocuronium is combined with Prednisolone.Approved
RofecoxibThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Rofecoxib.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Prednisolone.Approved
RolapitantThe serum concentration of Prednisolone can be increased when it is combined with Rolapitant.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Prednisolone.Approved, Investigational
RosoxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Prednisolone.Approved
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Prednisolone.Approved, Investigational
RucaparibThe serum concentration of Prednisolone can be increased when it is combined with Rucaparib.Approved, Investigational
RufloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Rufloxacin.Experimental
RuxolitinibThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ruxolitinib.Approved
SalbutamolThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Salbutamol.Approved, Vet Approved
SalicylamideThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prednisolone.Approved, Investigational, Vet Approved
SalinomycinThe serum concentration of Prednisolone can be increased when it is combined with Salinomycin.Vet Approved
SalmeterolThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Salmeterol.Approved
Salmonella typhi ty2 vi polysaccharide antigenThe therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Prednisolone.Approved
Salmonella typhi Ty21a live antigenThe risk or severity of infection can be increased when Salmonella typhi Ty21a live antigen is combined with Prednisolone.Approved
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Prednisolone.Approved
SalsalateThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Salsalate.Approved
SaquinavirThe serum concentration of Prednisolone can be increased when it is combined with Saquinavir.Approved, Investigational
SarafloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Sarafloxacin.Vet Approved, Withdrawn
SarilumabThe therapeutic efficacy of Prednisolone can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Prednisolone.Approved
SC-236The risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with SC-236.Experimental, Investigational
SecukinumabThe risk or severity of adverse effects can be increased when Secukinumab is combined with Prednisolone.Approved
SemaglutideThe therapeutic efficacy of Semaglutide can be decreased when used in combination with Prednisolone.Approved, Investigational
SeocalcitolThe therapeutic efficacy of Seocalcitol can be decreased when used in combination with Prednisolone.Experimental, Investigational
SertralineThe serum concentration of Prednisolone can be increased when it is combined with Sertraline.Approved
SiltuximabThe serum concentration of Prednisolone can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Prednisolone can be increased when it is combined with Simeprevir.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Prednisolone.Approved, Investigational
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Prednisolone.Approved, Investigational
SitafloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Sitafloxacin.Experimental, Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Prednisolone.Approved, Investigational
Sodium bicarbonateThe bioavailability of Prednisolone can be decreased when combined with Sodium bicarbonate.Approved
SorafenibThe risk or severity of adverse effects can be increased when Sorafenib is combined with Prednisolone.Approved, Investigational
SotagliflozinThe therapeutic efficacy of Sotagliflozin can be decreased when used in combination with Prednisolone.Investigational
SparfloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Sparfloxacin.Approved, Investigational
SRP 299The therapeutic efficacy of SRP 299 can be decreased when used in combination with Prednisolone.Investigational
St. John's WortThe serum concentration of Prednisolone can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StanoloneThe risk or severity of edema formation can be increased when Stanolone is combined with Prednisolone.Illicit, Investigational
StanozololThe risk or severity of fluid retention can be increased when Prednisolone is combined with Stanozolol.Approved, Vet Approved
StaurosporineThe serum concentration of Prednisolone can be increased when it is combined with Staurosporine.Experimental
SteproninThe risk or severity of adverse effects can be increased when Prednisolone is combined with Stepronin.Approved
StiripentolThe serum concentration of Prednisolone can be increased when it is combined with Stiripentol.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Streptozocin is combined with Prednisolone.Approved, Investigational
SuccinylcholineThe risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Prednisolone.Approved
SulfadiazineThe therapeutic efficacy of Sulfadiazine can be decreased when used in combination with Prednisolone.Approved, Investigational, Vet Approved
SulfamethoxazoleThe therapeutic efficacy of Sulfamethoxazole can be decreased when used in combination with Prednisolone.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Sulfasalazine.Approved
SulfisoxazoleThe therapeutic efficacy of Sulfisoxazole can be decreased when used in combination with Prednisolone.Approved, Vet Approved
SulindacThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Sulindac.Approved, Investigational
SunitinibThe risk or severity of adverse effects can be increased when Prednisolone is combined with Sunitinib.Approved, Investigational
SuprofenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Suprofen.Approved, Withdrawn
SuvorexantThe serum concentration of Prednisolone can be increased when it is combined with Suvorexant.Approved, Investigational
SuxibuzoneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Suxibuzone.Experimental
TacalcitolThe therapeutic efficacy of Tacalcitol can be decreased when used in combination with Prednisolone.Experimental, Investigational
TacrineThe therapeutic efficacy of Tacrine can be decreased when used in combination with Prednisolone.Investigational, Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Prednisolone.Approved, Investigational
TalniflumateThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Talniflumate.Approved
TamoxifenThe serum concentration of Prednisolone can be increased when it is combined with Tamoxifen.Approved
TariquidarThe serum concentration of Prednisolone can be increased when it is combined with Tariquidar.Investigational
TaspoglutideThe therapeutic efficacy of Taspoglutide can be decreased when used in combination with Prednisolone.Investigational
TecemotideThe therapeutic efficacy of Tecemotide can be decreased when used in combination with Prednisolone.Investigational
Technetium Tc-99m ciprofloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Technetium Tc-99m ciprofloxacin.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Tedizolid phosphate.Approved
TelaprevirThe serum concentration of Prednisolone can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Prednisolone can be increased when it is combined with Telithromycin.Approved
TelmisartanThe serum concentration of Prednisolone can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Temafloxacin.Withdrawn
TemozolomideThe risk or severity of adverse effects can be increased when Temozolomide is combined with Prednisolone.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Prednisolone is combined with Temsirolimus.Approved
TeneligliptinThe therapeutic efficacy of Teneligliptin can be decreased when used in combination with Prednisolone.Investigational
TenidapThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Tenidap.Experimental
TeniposideThe risk or severity of adverse effects can be increased when Teniposide is combined with Prednisolone.Approved
TenoxicamThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Tepoxalin.Vet Approved
TerbutalineThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Terbutaline.Approved
TerfenadineThe serum concentration of Prednisolone can be increased when it is combined with Terfenadine.Approved, Withdrawn
TergurideThe metabolism of Terguride can be decreased when combined with Prednisolone.Experimental
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Prednisolone.Approved
TesmilifeneThe serum concentration of Prednisolone can be increased when it is combined with Tesmilifene.Investigational
TestosteroneThe risk or severity of edema formation can be increased when Testosterone is combined with Prednisolone.Approved, Investigational
Testosterone cypionateThe risk or severity of edema formation can be increased when Testosterone cypionate is combined with Prednisolone.Approved
Testosterone enantate benzilic acid hydrazoneThe risk or severity of edema formation can be increased when Testosterone enantate benzilic acid hydrazone is combined with Prednisolone.Approved, Experimental
Testosterone enanthateThe risk or severity of edema formation can be increased when Testosterone enanthate is combined with Prednisolone.Approved
Testosterone propionateThe risk or severity of edema formation can be increased when Testosterone propionate is combined with Prednisolone.Approved, Investigational, Vet Approved, Withdrawn
Testosterone succinateThe risk or severity of edema formation can be increased when Testosterone succinate is combined with Prednisolone.Experimental
Testosterone undecanoateThe risk or severity of edema formation can be increased when Testosterone undecanoate is combined with Prednisolone.Approved, Investigational
TetrandrineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Tetrandrine.Experimental
TG4010The therapeutic efficacy of TG4010 can be decreased when used in combination with Prednisolone.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Prednisolone.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Thiotepa is combined with Prednisolone.Approved, Investigational
Tiaprofenic acidThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Tiaprofenic acid.Approved
TicagrelorThe serum concentration of Prednisolone can be increased when it is combined with Ticagrelor.Approved
TinoridineThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Tinoridine.Investigational
TioguanineThe risk or severity of adverse effects can be increased when Tioguanine is combined with Prednisolone.Approved
TipifarnibThe serum concentration of Prednisolone can be increased when it is combined with Tipifarnib.Investigational
TipranavirThe serum concentration of Prednisolone can be increased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Prednisolone is combined with Tixocortol.Approved, Withdrawn
TocilizumabThe serum concentration of Prednisolone can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe risk or severity of adverse effects can be increased when Tofacitinib is combined with Prednisolone.Approved, Investigational
TofacitinibPrednisolone may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Prednisolone.Approved, Investigational
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Prednisolone.Approved, Investigational
Tolfenamic AcidThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Tolmetin.Approved
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Prednisolone.Approved
TopotecanThe risk or severity of adverse effects can be increased when Prednisolone is combined with Topotecan.Approved, Investigational
TorasemideThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Torasemide.Approved
ToremifeneThe serum concentration of Prednisolone can be increased when it is combined with Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Tositumomab is combined with Prednisolone.Approved, Investigational
TrabectedinThe risk or severity of adverse effects can be increased when Prednisolone is combined with Trabectedin.Approved, Investigational
TrastuzumabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Trastuzumab.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Trastuzumab emtansine.Approved, Investigational
TrestoloneThe risk or severity of edema formation can be increased when Trestolone is combined with Prednisolone.Investigational
Trestolone acetateThe risk or severity of edema formation can be increased when Trestolone acetate is combined with Prednisolone.Experimental
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Prednisolone.Approved, Investigational, Nutraceutical
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Prednisolone.Approved, Vet Approved
TrichlorfonThe therapeutic efficacy of Trichlorfon can be decreased when used in combination with Prednisolone.Vet Approved
TrichlormethiazidePrednisolone may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe serum concentration of Prednisolone can be increased when it is combined with Trifluoperazine.Approved, Investigational
TriflupromazineThe serum concentration of Prednisolone can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrifluridineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Trifluridine.Approved, Investigational
TrilostaneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe serum concentration of Prednisolone can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Triptolide.Investigational
TrofosfamideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Trofosfamide.Investigational
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Prednisolone.Investigational, Withdrawn
Trolamine salicylateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prednisolone.Approved
TroleandomycinThe serum concentration of Prednisolone can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of tendinopathy can be increased when Prednisolone is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TubocurarineThe risk or severity of myopathy and weakness can be increased when Tubocurarine is combined with Prednisolone.Approved
Typhoid VaccineThe therapeutic efficacy of Typhoid Vaccine can be decreased when used in combination with Prednisolone.Approved
TyrothricinThe therapeutic efficacy of Tyrothricin can be decreased when used in combination with Prednisolone.Approved
UlipristalThe serum concentration of Prednisolone can be increased when it is combined with Ulipristal.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ulobetasol.Approved
UstekinumabThe risk or severity of adverse effects can be increased when Ustekinumab is combined with Prednisolone.Approved, Investigational
ValdecoxibThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValinomycinThe serum concentration of Prednisolone can be increased when it is combined with Valinomycin.Experimental
ValspodarThe serum concentration of Prednisolone can be increased when it is combined with Valspodar.Investigational
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of infection can be increased when Varicella Zoster Vaccine (Live/Attenuated) is combined with Prednisolone.Approved
Varicella Zoster Vaccine (Live/Attenuated)The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Prednisolone.Approved
VecuroniumThe risk or severity of myopathy and weakness can be increased when Vecuronium is combined with Prednisolone.Approved
VedolizumabThe risk or severity of adverse effects can be increased when Vedolizumab is combined with Prednisolone.Approved
VelpatasvirThe serum concentration of Prednisolone can be increased when it is combined with Velpatasvir.Approved, Investigational
VemurafenibThe serum concentration of Prednisolone can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Prednisolone can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Prednisolone can be increased when it is combined with Verapamil.Approved
Vibrio cholerae CVD 103-HgR strain live antigenThe risk or severity of infection can be increased when Vibrio cholerae CVD 103-HgR strain live antigen is combined with Prednisolone.Approved, Investigational
Vibrio cholerae CVD 103-HgR strain live antigenThe therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Prednisolone.Approved, Investigational
VilanterolThe risk or severity of adverse effects can be increased when Prednisolone is combined with Vilanterol.Approved
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Prednisolone.Approved, Investigational
VinblastineThe risk or severity of adverse effects can be increased when Vinblastine is combined with Prednisolone.Approved
VincristineThe risk or severity of adverse effects can be increased when Vincristine is combined with Prednisolone.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Vindesine is combined with Prednisolone.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Vinorelbine is combined with Prednisolone.Approved, Investigational
Vitamin DThe therapeutic efficacy of Vitamin D can be decreased when used in combination with Prednisolone.Approved, Nutraceutical, Vet Approved
VoacamineThe serum concentration of Prednisolone can be increased when it is combined with Voacamine.Approved, Investigational
VoclosporinThe risk or severity of adverse effects can be increased when Voclosporin is combined with Prednisolone.Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Prednisolone.Approved, Investigational
VorapaxarThe serum concentration of Prednisolone can be increased when it is combined with Vorapaxar.Approved
VoriconazoleThe serum concentration of Prednisolone can be increased when it is combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of adverse effects can be increased when Prednisolone is combined with Vorinostat.Approved, Investigational
VoxilaprevirThe serum concentration of Prednisolone can be increased when it is combined with Voxilaprevir.Approved, Investigational
WarfarinThe therapeutic efficacy of Warfarin can be increased when used in combination with Prednisolone.Approved
WortmanninThe risk or severity of adverse effects can be increased when Prednisolone is combined with Wortmannin.Experimental
Yellow Fever VaccineThe risk or severity of infection can be increased when Yellow Fever Vaccine is combined with Prednisolone.Approved, Investigational
Yellow Fever VaccineThe therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Prednisolone.Approved, Investigational
YohimbineThe serum concentration of Prednisolone can be increased when it is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaltoprofenThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Zidovudine.Approved
ZiprasidoneThe metabolism of Prednisolone can be decreased when combined with Ziprasidone.Approved
ZomepiracThe serum concentration of Prednisolone can be increased when it is combined with Zomepirac.Withdrawn
ZosuquidarThe serum concentration of Prednisolone can be increased when it is combined with Zosuquidar.Investigational
Food Interactions
  • Avoid alcohol. Avoid caffeine.
  • Take with food to reduce gastric irritation.

References

Synthesis Reference

Gunther Bellmann, "Process for producing a sterile prednisolone gel." U.S. Patent US5811417, issued September 22, 1998.

US5811417
General References
Not Available
External Links
Human Metabolome Database
HMDB0014998
KEGG Drug
D00472
KEGG Compound
C07369
PubChem Compound
5755
PubChem Substance
46504847
ChemSpider
5552
BindingDB
19190
ChEBI
8378
ChEMBL
CHEMBL131
Therapeutic Targets Database
DAP000419
PharmGKB
PA451096
IUPHAR
2866
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Prednisolone
ATC Codes
D07AA03 — PrednisoloneR01AD52 — Prednisolone, combinationsS02BA03 — PrednisoloneS01CA02 — Prednisolone and antiinfectivesV03AB05 — Prednisolone and promethazineD07XA02 — PrednisoloneD07CA03 — Prednisolone and antibioticsS01CB02 — PrednisoloneC05AA04 — PrednisoloneA07EA01 — PrednisoloneS02CA01 — Prednisolone and antiinfectivesS03BA02 — PrednisoloneA01AC54 — Prednisolone, combinationsR01AD02 — PrednisoloneS03CA02 — Prednisolone and antiinfectivesH02AB06 — PrednisoloneS01BB02 — Prednisolone and mydriaticsD07BA01 — Prednisolone and antisepticsS01BA04 — Prednisolone
AHFS Codes
  • 68:04.00 — Adrenals
  • 52:08.00 — Anti-inflammatory Agents
  • 52:08.08 — Corticosteroids
FDA label
Download (101 KB)
MSDS
Download (72.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Not Yet RecruitingTreatmentOtitis Media With Effusion1
0WithdrawnDiagnosticSevere Alcoholic Hepatitis1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHealthy Volunteers / Pharmacodynamics / Pharmacokinetics / Rheumatoid Arthritis / Safety / Tolerability1
1CompletedBasic ScienceHealthy Volunteers / Pulmonary Disease, Chronic Obstructive1
1CompletedBasic ScienceImmunoscience1
1CompletedOtherInflammatory Reaction1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
1CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Disease, Chronic Obstructive1
1CompletedTreatmentHealthy Volunteers2
1CompletedTreatmentMultiple Myeloma (MM)1
1CompletedTreatmentProstate Cancer1
1CompletedTreatmentPulmonary Disease, Chronic Obstructive1
1CompletedTreatmentRheumatoid Arthritis1
1Not Yet RecruitingTreatmentWet Age-Related Macular Degeneration1
1RecruitingPreventionEsophageal Anastomotic Stricture1
1RecruitingTreatmentStatus Asthmaticus1
1TerminatedTreatmentAsthma Bronchial1
1TerminatedTreatmentFollicular Lymphoma (FL)1
1Unknown StatusTreatmentLymphoma, Hodgkins1
1Unknown StatusTreatmentMalignant Lymphomas1
1Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
1, 2Active Not RecruitingTreatmentLymphoma, B-Cell, Non-Hodgkin's Lymphoma / Non Hodgkin Lymphoma (NHL)1
1, 2Active Not RecruitingTreatmentProstate Cancer1
1, 2CompletedBasic ScienceHealthy Volunteers1
1, 2CompletedTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T Cell Lymphoma / Cutaneous T Cell Lymphomas (CTCL) / Peripheral T Cell Lymphoma Unspecified1
1, 2CompletedTreatmentLipomas1
1, 2CompletedTreatmentLymphoma, B-Cell / Lymphoma, Large-Cell, Diffuse1
1, 2CompletedTreatmentNon-Infectious Anterior Uveitis1
1, 2CompletedTreatmentProstate Cancer1
1, 2RecruitingTreatmentDiffuse B-Cell Lymphoma1
1, 2SuspendedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2Unknown StatusTreatmentMalignant Lymphomas1
2Active Not RecruitingSupportive CareLymphoma, Large B-Cell, Diffuse (DLBCL)2
2Active Not RecruitingSupportive CareMalignant Tumor of Breast / Neoplasm of the Breast / Oral Mucositis / Vesicular Stomatitis1
2Active Not RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Angioimmunoblastic T-Cell Lymphoma / Enteropathy-Associated T-Cell Lymphoma / Hepatosplenic Gamma/ Delta T-cell Lymphoma / Peripheral T-cell Lymphoma NOS1
2Active Not RecruitingTreatmentLymphoma, Lymphoblastic1
2Active Not RecruitingTreatmentLymphoproliferative Disorders1
2Active Not RecruitingTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentStage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
2Active Not RecruitingTreatmentSteroids In Management Of Acute Asthma Exacerbations1
2CompletedNot AvailableAsthma Bronchial1
2CompletedBasic ScienceCataracts1
2CompletedBasic ScienceWhole Body Catabolisme Induced by Glucocorticoids1
2CompletedPreventionBullous Keratopathy / Fuchs' Dystrophy1
2CompletedPreventionMacular Edema (ME)1
2CompletedSupportive CarePostoperative pain / Prophylaxis against postoperative nausea and vomiting1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2CompletedTreatmentAlcoholic Hepatitis (AH)2
2CompletedTreatmentBronchial Asthma1
2CompletedTreatmentConjunctivitis, Seasonal Allergic1
2CompletedTreatmentConnective Tissue Diseases / Dermatomyositis / Vasculitis / Vasculitis, Hypersensitivity1
2CompletedTreatmentDuchenne's Muscular Dystrophy (DMD)1
2CompletedTreatmentGranulomatosis With Polyangiitis / Microscopic Polyangiitis / Renal Limited Vasculitis1
2CompletedTreatmentHIV Disease Progression1
2CompletedTreatmentHansen's Disease2
2CompletedTreatmentHormone Refractory / Metastatic / Prostate Cancer1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
2CompletedTreatmentLeukemias1
2CompletedTreatmentLymphoma, B-Cell1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentMacular Edema After Cataract Surgery in Patients With Diabetes Mellitus1
2CompletedTreatmentMalignant Lymphomas3
2CompletedTreatmentMalignant Lymphomas / Neurotoxicity1
2CompletedTreatmentMetastatic Cancers / Prostate Cancer1
2CompletedTreatmentNephritis, Lupus2
2CompletedTreatmentNon-Infectious Anterior Uveitis1
2CompletedTreatmentProstate Cancer3
2CompletedTreatmentRheumatoid Arthritis4
2Enrolling by InvitationPreventionIritis1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Childhood Cancers / Down Syndrome (DS)1
2Not Yet RecruitingTreatmentCognitive Change / Immune Suppression / Psychosis / Schizophrenia and Related Disorders1
2RecruitingTreatmentAcanthamoeba Keratitis1
2RecruitingTreatmentAcute Interstitial Nephritis1
2RecruitingTreatmentAcute Leukemias of Ambiguous Lineage / Childhood B Acute Lymphoblastic Leukemia / KMT2A Gene Rearrangement / Mixed Phenotype Acute Leukemia (MPAL)1
2RecruitingTreatmentAutoimmune Diseases1
2RecruitingTreatmentCerebral Radiation Necrosis1
2RecruitingTreatmentEpstein-Barr Virus-positive Diffuse Large B-cell Lymphoma1
2RecruitingTreatmentIatrogenic Cushing's Disease1
2RecruitingTreatmentKaposiform Hemangioendothelioma / Kasabach Merritt Phenomenon1
2RecruitingTreatmentLymphoma, Hodgkins1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentMyocardial Inflammation1
2RecruitingTreatmentNon Hodgkin Lymphoma (NHL)1
2RecruitingTreatmentRheumatoid Arthritis1
2SuspendedTreatmentAllergic Alveolitis1
2TerminatedBasic ScienceDependence, Cocaine / Opioid Dependence1
2TerminatedTreatmentHemangiomas2
2TerminatedTreatmentHemangiomas of Infancy1
2TerminatedTreatmentKnee Osteoarthritis (Knee OA)1
2TerminatedTreatmentMultiple Myeloma (MM)1
2Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2Unknown StatusTreatmentCancer, Breast1
2Unknown StatusTreatmentLeukemias3
2Unknown StatusTreatmentMalignant Lymphomas2
2Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
2Unknown StatusTreatmentRenal Insufficiency,Chronic / Transplantation, Liver1
2Unknown StatusTreatmentStomatitis, Aphthous1
2WithdrawnTreatmentLPL Deficiency1
2, 3Active Not RecruitingTreatmentRetinal Vein Occlusions(RVO)1
2, 3CompletedDiagnosticRheumatoid Arthritis1
2, 3CompletedTreatmentAspergillosis, Allergic Bronchopulmonary2
2, 3CompletedTreatmentGluten Enteropathy1
2, 3CompletedTreatmentHansen's Disease1
2, 3CompletedTreatmentInfertilities1
2, 3CompletedTreatmentPolymyalgia Rheumatica1
2, 3Not Yet RecruitingTreatmentIgA Nephropathy1
2, 3RecruitingOtherInfertilities1
2, 3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Lymphoblastic Lymphoma1
2, 3RecruitingTreatmentBell's Palsy / Facial Nerve Paresis1
2, 3RecruitingTreatmentIgA Nephropathy at High Risk of Developing ESRD / Progressive IgA Nephropathy1
2, 3RecruitingTreatmentProstate Cancer1
2, 3Unknown StatusTreatmentAnkylosing Spondylitis (AS)1
3Active Not RecruitingTreatmentChurg-Strauss Syndrome (CSS)1
3Active Not RecruitingTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias1
3Active Not RecruitingTreatmentFollicular Lymphoma (FL)1
3Active Not RecruitingTreatmentMalignant Lymphomas2
3Active Not RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
3Active Not RecruitingTreatmentProgression of Rheumatoid Arthritis1
3Active Not RecruitingTreatmentProstatic Neoplasms1
3CompletedNot AvailableUveitis1
3CompletedBasic ScienceCataracts1
3CompletedPreventionAcute Urinary Tract Infection / Urinary Tract Infections (UTIs)1
3CompletedPreventionTransplantation, Kidney1
3CompletedTreatmentActive Rheumatoid Arthritis1
3CompletedTreatmentAcute Exacerbation of Chronic Obstructive Pulmonary Disease1
3CompletedTreatmentAlcoholic Hepatitis (AH) / Severe alcoholic liver disease1
3CompletedTreatmentAllergic Rhinitis (AR)1
3CompletedTreatmentAnemia, Hemolytic, Autoimmune1
3CompletedTreatmentAnterior Uveitis (AU)1
3CompletedTreatmentAsthma Bronchial3
3CompletedTreatmentAsthma Bronchial / Wheezing1
3CompletedTreatmentCancers / Carcinoma NOS / Malignant Ascites / Neoplasms1
3CompletedTreatmentCataracts1
3CompletedTreatmentCataracts / Inflammatory Reaction1
3CompletedTreatmentCataracts / Non-Proliferative Diabetic Retinopathy2
3CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
3CompletedTreatmentDermatomyositis / Polymyositis1
3CompletedTreatmentEndogenous Anterior Uveitis1
3CompletedTreatmentEye Infections / Postoperative Complications1
3CompletedTreatmentGlomerulonephritis, Membranous1
3CompletedTreatmentGlomerulonephritis, Membranous / Glomerulosclerosis, Focal Segmental1
3CompletedTreatmentGlomerulonephritis, Membranous / Nephritis, Lupus1
3CompletedTreatmentHeadaches1
3CompletedTreatmentHemangiomas1
3CompletedTreatmentHepatocellular,Carcinoma1
3CompletedTreatmentIdiopathic Thrombocytopenic Purpura (ITP)1
3CompletedTreatmentInfantile Spasms (IS) / West Syndrome1
3CompletedTreatmentInfection and Inflammation After Refractive Surgery (Lasik) / Ocular Infection and Inflammation1
3CompletedTreatmentLeukemias3
3CompletedTreatmentLeukemias / Malignant Lymphomas2
3CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3CompletedTreatmentMalignant Lymphomas4
3CompletedTreatmentMultiple Myeloma (MM)2
3CompletedTreatmentMyasthenia Gravis1
3CompletedTreatmentProstatic Neoplasms1
3CompletedTreatmentTransplantation, Renal1
3CompletedTreatmentTuberculous Pericarditis1
3CompletedTreatmentUlcerative Colitis (UC)1
3Not Yet RecruitingTreatmentArterial Ischemic Stroke1
3Not Yet RecruitingTreatmentCongenital Adrenal Hyperplasia (CAH)1
3Not Yet RecruitingTreatmentGlomerulonephritis minimal lesion / Glomerulosclerosis, Focal Segmental / Idiopathic Nephrotic Syndrome1
3Not Yet RecruitingTreatmentPolymyalgia Rheumatica1
3RecruitingSupportive CarePulpitis dental1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
3RecruitingTreatmentAlcoholic Hepatitis (AH) / Severe alcoholic liver disease1
3RecruitingTreatmentCongenital Adrenal Hyperplasia (CAH)1
3RecruitingTreatmentDisseminated Sclerosis1
3RecruitingTreatmentGlomerulonephritis minimal lesion1
3RecruitingTreatmentGraves Diseases / Hyperthyroidism1
3RecruitingTreatmentIdiopathic Pulmonary Fibrosis (IPF)1
3RecruitingTreatmentImmune Thrombocytopenia1
3RecruitingTreatmentImmuoglobulin / Mucocutaneous Lymph Node Syndrome / Steroid1
3RecruitingTreatmentInfantile Spasms (IS)1
3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
3RecruitingTreatmentOcular inflammatory conditions1
3SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3TerminatedHealth Services ResearchFollicular Lymphoma (FL)1
3TerminatedTreatmentCrohn's Disease (CD)1
3TerminatedTreatmentCutaneous Hypersensitivity1
3TerminatedTreatmentDiscal Sciatica1
3TerminatedTreatmentEvidence of Liver Transplantation / Transplantations1
3TerminatedTreatmentMalignant Lymphomas1
3TerminatedTreatmentNephritis, Lupus1
3TerminatedTreatmentPemphigus1
3TerminatedTreatmentSystemic Lupus Erythematosus, Lupus Nephritis1
3TerminatedTreatmentUlcerative Colitis (UC)1
3Unknown StatusTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3Unknown StatusTreatmentAlcoholic Hepatitis (AH)1
3Unknown StatusTreatmentAllergic Rhinitis (AR)1
3Unknown StatusTreatmentAtopic Dermatitis (AD) / Dermatitis, Contact / Psoriasis / Seborrheic Dermatitis1
3Unknown StatusTreatmentBiliary Atresia1
3Unknown StatusTreatmentFollicular Lymphoma (FL)1
3Unknown StatusTreatmentInfantile Spasms (IS)1
3Unknown StatusTreatmentLeukemias1
3Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
3Unknown StatusTreatmentMalignant Lymphomas3
3Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
3Unknown StatusTreatmentRheumatoid Arthritis1
3Unknown StatusTreatmentDiffuse posterior uveitis1
3WithdrawnTreatmentNephritis, Lupus1
4Active Not RecruitingTreatmentConjunctivitis, Giant Papillary / Conjunctivitis, Seasonal Allergic / Inflammatory Reaction1
4Active Not RecruitingTreatmentCorneal Transplant / Grafting, Corneal / Keratoplasty, Lamellar / Transplantation, Cornea / Transplantation, Corneal1
4Active Not RecruitingTreatmentProstate Cancer1
4Active Not RecruitingTreatmentRheumatoid Arthritis1
4Active Not RecruitingTreatmentSeasonal Allergic Rhinitis (SAR)1
4CompletedNot AvailableAsthma Bronchial1
4CompletedNot AvailableCataract operation1
4CompletedNot AvailableMacula Thickening1
4CompletedDiagnosticCoughing1
4CompletedPreventionCataracts1
4CompletedPreventionChronic Allergic Conjunctivitis1
4CompletedPreventionConjunctivitis, Seasonal Allergic1
4CompletedPreventionCorneal Edema / Fuchs' Dystrophy1
4CompletedPreventionRenal Transplanted Recipients1
4CompletedPreventionTracheal Stenosis1
4CompletedPreventionTransplantation, Kidney1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4CompletedTreatmentAdult Acute Lymphocytic Leukemia3
4CompletedTreatmentAsthma Acute / Asthma Bronchial / Reactive Airway Exacerbation1
4CompletedTreatmentAsthma Bronchial3
4CompletedTreatmentAtopic Dermatitis (AD)1
4CompletedTreatmentBell's Palsy1
4CompletedTreatmentBurkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms1
4CompletedTreatmentCataract operation1
4CompletedTreatmentCataracts2
4CompletedTreatmentCataracts / Corneal Edema / Retinal Structural Change, Deposit and Degeneration / Visual Acuity Reduced Transiently1
4CompletedTreatmentCataracts / Dry Eye Syndromes1
4CompletedTreatmentCataracts / Glaucoma1
4CompletedTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4CompletedTreatmentConjunctivitis, Seasonal Allergic1
4CompletedTreatmentDisease, Chronic / Idiopathic eosinophilic pneumonias1
4CompletedTreatmentFulminant Hepatic Failure1
4CompletedTreatmentGlaucoma1
4CompletedTreatmentGlomerulonephritis minimal lesion1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHemangiomas1
4CompletedTreatmentLymphoma, Lymphoblastic1
4CompletedTreatmentMCNS / Minimal Change Nephrotic Syndrome (MCNS)1
4CompletedTreatmentMeibomian Gland Dysfunction (MGD)1
4CompletedTreatmentMetastatic Castration Resistant Prostate Cancer1
4CompletedTreatmentMetastatic Hormone Refractory Prostate Cancer1
4CompletedTreatmentOptic Disk / Regional Blood Flow1
4CompletedTreatmentOral Lichen Planus1
4CompletedTreatmentPain1
4CompletedTreatmentPolyps, Nasal1
4CompletedTreatmentProstate Cancer1
4CompletedTreatmentPulpitis dental1
4CompletedTreatmentRejection, Transplant / Renal Failure / Transplantation, Kidney1
4CompletedTreatmentRenal Function1
4CompletedTreatmentRheumatoid Arthritis1
4CompletedTreatmentSepsis1
4Enrolling by InvitationTreatmentCorticotropin Deficiency / Fasting1
4Enrolling by InvitationTreatmentCrohn's Disease (CD)1
4Not Yet RecruitingOtherAsthma Bronchial1
4Not Yet RecruitingPreventionEsophageal Strictures / Esophagus, Barrett1
4Not Yet RecruitingTreatmentBenign Childhood Epilepsy With Centrotemporal Spikes1
4Not Yet RecruitingTreatmentCystoid Macular Edema / Macular Edema (ME) / Uveitis1
4RecruitingPreventionCataracts1
4RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4RecruitingTreatmentAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / Granulomatosis With Polyangiitis / Microscopic Polyangiitis1
4RecruitingTreatmentBlood Eosinophil Count / Chronic Obstructive Pulmonary Disease (COPD) / Glucocorticoid therapy / Lung Diseases, Obstructive / Pulmonary Disease, Chronic Obstructive1
4RecruitingTreatmentChoroidal Effusions / Glaucoma1
4RecruitingTreatmentDrug Interaction Potentiation / Transplantation, Kidney1
4RecruitingTreatmentEpilepsy, Unspecified, Intractable1
4RecruitingTreatmentFunction of Renal Transplant1
4RecruitingTreatmentGlomerulonephritis minimal lesion2
4RecruitingTreatmentIgA Nephropathy1
4RecruitingTreatmentImmunoglobulin G4 Related Sclerosing Disease1
4RecruitingTreatmentInfertilities / Polycystic Ovarian Syndrome1
4RecruitingTreatmentMalignant Lymphomas1
4RecruitingTreatmentMycoplasma Pneumoniae Pneumonia1
4RecruitingTreatmentOphthalmopathy, Thyroid-Associated1
4RecruitingTreatmentPsychotic Disorder NOS / Schizoaffective Disorders / Schizophrenic Disorders / Schizophreniform Disorder1
4RecruitingTreatmentRecurrent IgA Nephropathy1
4RecruitingTreatmentRheumatoid Arthritis2
4RecruitingTreatmentSarcoidosis1
4RecruitingTreatmentUlcerative Colitis (UC)1
4RecruitingTreatmentVestibular Diseases / Vestibular Neuronitis1
4TerminatedTreatmentAsthma Bronchial / Status Asthmaticus / Wheezing1
4TerminatedTreatmentImmune Reconstitution Inflammatory Syndrome / Progressive Multifocal Leukoencephalopathy1
4TerminatedTreatmentObstructive Sleep Apnea Syndrome (OSAS)1
4Unknown StatusPreventionCataract operation / Pseudophakia1
4Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia2
4Unknown StatusTreatmentCataracts1
4Unknown StatusTreatmentCrohn's Disease (CD)1
4Unknown StatusTreatmentDisorder Related to Renal Transplantation1
4Unknown StatusTreatmentHepatitis B Chronic Infection1
4Unknown StatusTreatmentWheezing1
Not AvailableActive Not RecruitingBasic ScienceAsthma Bronchial / Chronic Obstructive Pulmonary Disease (COPD)1
Not AvailableActive Not RecruitingTreatmentMalignant Lymphomas1
Not AvailableCompletedNot AvailableHemangiomas1
Not AvailableCompletedBasic ScienceElectroretinography1
Not AvailableCompletedPreventionBeta-cell Function / Diabetes Mellitus (DM) / Glucocorticoid-induced Diabetes / Steroid Diabetes1
Not AvailableCompletedPreventionEpiretinal Membrane1
Not AvailableCompletedPreventionPatients With Systemic Inflammatory Diseases Receiving for the First Time a Protracted General Corticostroid Therapy1
Not AvailableCompletedTreatmentBiliary Atresia1
Not AvailableCompletedTreatmentCarpal Tunnel Syndrome (CTS)1
Not AvailableCompletedTreatmentChildhood Langerhans Cell Histiocytosis1
Not AvailableCompletedTreatmentCorneal Neovascularization1
Not AvailableCompletedTreatmentDrug hypersensitivity reaction1
Not AvailableCompletedTreatmentFacial Paralysis1
Not AvailableCompletedTreatmentGlaucoma1
Not AvailableCompletedTreatmentGlaucoma, Primary Open Angle (POAG) / Pseudoexfoliation Syndrome1
Not AvailableCompletedTreatmentGlucocorticoid-induced Beta-cell Dysfunction / Glucocorticoid-induced Glucometabolic Abnormalities1
Not AvailableCompletedTreatmentGlucose tolerance impaired / Hyperglycemias / Insulin Resistance1
Not AvailableCompletedTreatmentIgA Nephropathy1
Not AvailableCompletedTreatmentModerate to Severe Atopic Dermatitis1
Not AvailableCompletedTreatmentReproductive Sterility1
Not AvailableCompletedTreatmentScleral Buckling1
Not AvailableCompletedTreatmentTuberculous Pleurisy1
Not AvailableNot Yet RecruitingTreatmentTonsillectomy1
Not AvailableRecruitingNot AvailableDegeneration / Ectasia / Keratoconus2
Not AvailableRecruitingNot AvailableIgA Nephropathy / Immunosuppressive Treatment / Proteinuria in Nephrotic Range1
Not AvailableRecruitingHealth Services ResearchHypospadias1
Not AvailableRecruitingTreatmentAllergies / Urticarias1
Not AvailableRecruitingTreatmentCorneal Graft Rejection1
Not AvailableRecruitingTreatmentLumbar Discogenic Pain (Disorder)1
Not AvailableTerminatedNot AvailableProstatic Neoplasms1
Not AvailableTerminatedTreatmentDrug Induced Liver Injury1
Not AvailableTerminatedTreatmentOpen Angle Glaucoma (OAG)1
Not AvailableUnknown StatusNot AvailableAsthma Exacerbations1
Not AvailableUnknown StatusNot AvailableScleritis / Uveitis1
Not AvailableUnknown StatusPreventionAsthma Bronchial1
Not AvailableUnknown StatusSupportive CareNon-Hodgkin's Lymphoma (NHL)1
Not AvailableUnknown StatusTreatmentBehcet's Syndrome / Uveal Disease1
Not AvailableUnknown StatusTreatmentBell's Palsy1
Not AvailableUnknown StatusTreatmentLeukemias2
Not AvailableUnknown StatusTreatmentMalignant Lymphomas3
Not AvailableWithdrawnNot AvailableAcute Lymphoblastic Leukaemias (ALL) / Leukemias / Untreated Childhood Acute Lymphoblastic Leukemia1
Not AvailableWithdrawnTreatmentBronchiolitis1

Pharmacoeconomics

Manufacturers
  • Pharmacia and upjohn co
  • Akorn inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Bel mar laboratories inc
  • Schering corp sub schering plough corp
  • Alpharma uspd inc
  • Apotex inc richmond hill
  • Hi tech pharmacal co inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Vintage pharmaceuticals llc
  • We pharmaceuticals inc
  • Wockhardt eu operations (swiss) ag
  • Muro pharmaceutical inc
  • Teva pharmaceuticals usa inc
  • Halsey drug co inc
  • Ferndale laboratories inc
  • Barr laboratories inc
  • Cm bundy co
  • Elkins sinn div ah robins co inc
  • Everylife
  • John j ferrante
  • Heather drug co inc
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Lannett co inc
  • Marshall pharmacal corp
  • Panray corp sub ormont drug and chemical co inc
  • L perrigo co
  • Phoenix laboratories inc
  • Purepac pharmaceutical co
  • Private formulations inc
  • Roxane laboratories inc
  • Sandoz inc
  • Sperti drug products inc
  • Superpharm corp
  • Tablicaps inc
  • Udl laboratories inc
  • Valeant pharmaceuticals international
  • Vitarine pharmaceuticals inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Pfizer laboratories div pfizer inc
  • Central pharmaceuticals inc
  • Alcon laboratories inc
  • Allergan pharmaceutical
  • Taro pharmaceuticals usa inc
  • Merck and co inc
  • Novartis pharmaceuticals corp
  • Pharmafair inc
  • Alcon universal ltd
  • Bausch and lomb pharmaceuticals inc
  • Sola barnes hind
  • Shionogi pharma inc
  • Ucb inc
  • Amneal pharmaceuticals
  • Paddock laboratories inc
  • Pharmaceutical assoc inc
Packagers
  • Adamis Laboratories
  • Aidarex Pharmacuticals LLC
  • Akorn Inc.
  • Alcon Laboratories
  • Allergan Inc.
  • Amend
  • Amneal Pharmaceuticals
  • A-S Medication Solutions LLC
  • Atlantic Biologicals Corporation
  • Bausch & Lomb Inc.
  • Bedford Labs
  • Ben Venue Laboratories Inc.
  • BioMarin Pharmaceuticals Inc.
  • Blansett Pharmacal Co. Inc.
  • Bryant Ranch Prepack
  • C.O. Truxton Inc.
  • Cardinal Health
  • Carlisle Laboratories Inc.
  • Cima Laboratories Inc.
  • Clint Pharmaceutical Inc.
  • Consolidated Midland Corp.
  • Darby Dental Supply Co. Inc.
  • Dexo LLC
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Ethex Corp.
  • Falcon Pharmaceuticals Ltd.
  • Hawthorn Pharmaceuticals
  • Hi Tech Pharmacal Co. Inc.
  • Keene Pharmaceuticals Inc.
  • KV Pharmaceutical Co.
  • Lake Erie Medical and Surgical Supply
  • Laser Pharmaceuticals
  • Lunsco Inc.
  • Lyne Laboratories Inc.
  • Major Pharmaceuticals
  • Marpac
  • Martica Enterprises Inc.
  • Martin Surgical Supply
  • Medisca Inc.
  • Merit Pharmaceuticals
  • MWI Veterinary Supply Co.
  • National Pharmaceuticals
  • Novartis AG
  • Ocusoft
  • OMJ Pharmaceuticals
  • Pacific Pharma Lp
  • Paddock Labs
  • Palmetto Pharmaceuticals Inc.
  • Pfizer Inc.
  • Pharmaceutical Association
  • Pharmacia Inc.
  • Pharmedix
  • Physicians Total Care Inc.
  • Preferred Pharmaceuticals Inc.
  • Prescript Pharmaceuticals
  • Primedics Laboratories
  • Qualitest
  • Rebel Distributors Corp.
  • San Jose Surgical Supply Inc.
  • Sandoz
  • Sciele Pharma Inc.
  • Shionogi Pharma Inc.
  • Stat Rx Usa
  • Taro Pharmaceuticals USA
  • Teva Pharmaceutical Industries Ltd.
  • UCB Pharma
  • Upstate Pharma LLC
  • Vedco Inc.
  • Vintage Pharmaceuticals Inc.
  • Wa Butler Co.
  • Watson Pharmaceuticals
  • Wockhardt Ltd.
Dosage forms
FormRouteStrength
OintmentOphthalmic
Suspension / dropsOphthalmic
Solution / dropsOphthalmic
OintmentOphthalmic; Topical
SuspensionOral15 mg/5mL
LiquidOphthalmic10 mg
SolutionOphthalmic1 %
LiquidOphthalmic.125 %
LiquidOphthalmic1.25 mg
SuspensionOphthalmic
SolutionOral10 mg/5mL
TabletOral5 mg/1
TabletOral5 mg/5mg
Solution / dropsOphthalmic0.5 %
TabletOral5 mg
Tablet, orally disintegratingOral10 mg/1
Tablet, orally disintegratingOral15 mg/1
Tablet, orally disintegratingOral30 mg/1
LiquidOral5 mg
SolutionOral5 mg
Suspension / dropsOphthalmic1.2 mg/mL
Solution / dropsOphthalmic0.12 %
SyrupOral15 mg/5mL
SyrupOral5 mg/5mL
SuspensionOphthalmic10 mg/mL
Suspension / dropsOphthalmic10 mg/mL
Suspension / dropsOphthalmic10 mg/1
SolutionOral15 mg/5mL
SolutionOral5 mg/5mL
Solution / dropsOphthalmic10 mg/mL
SolutionOral25 mg/5mL
Liquid; solution / dropsOphthalmic1 %
SuspensionOphthalmic0.12 %
SuspensionOphthalmic1 %
SolutionOphthalmic
LiquidOphthalmic
SolutionOral20 mg/5mL
Prices
Unit descriptionCostUnit
Orapred ODT 48 15 mg Dispersible Tablet Box289.42USD box
Pred Forte 1% Suspension 15ml Bottle97.79USD bottle
PrednisoLONE Sodium Phosphate 1% Solution 10ml Bottle72.82USD bottle
Pred Forte 1% Suspension 10ml Bottle68.06USD bottle
Econopred Plus 1% Suspension 10ml Bottle63.44USD bottle
Solu-Medrol Act-O-Vial 1 g/vial61.25USD vial
Solu-Medrol 1 g/vial60.04USD vial
Pediapred 6.7 mg/5ml Solution 120ml Bottle57.77USD bottle
Pred Mild 0.12% Suspension 10ml Bottle44.33USD bottle
Econopred Plus 1% Suspension 5ml Bottle40.99USD bottle
Solu-Medrol Act-O-Vial 500 mg/vial39.96USD vial
Medrol (Pak) 21 4 mg tablet Disp Pack39.3USD disp
Solu-Medrol 500 mg/vial39.17USD vial
Pred Forte 1% Suspension 5ml Bottle37.12USD bottle
Prednisolone sod ph powder36.11USD g
PrednisoLONE Acetate 1% Suspension 15ml Bottle35.46USD bottle
PrednisoLONE Sodium Phosphate 1% Solution 15ml Bottle34.41USD bottle
Pred Mild 0.12% Suspension 5ml Bottle33.98USD bottle
Methylprednisolone Sod Succin. 1 g/vial32.47USD vial
Solu-medrol 1 gm vial24.43USD vial
PrednisoLONE Acetate 1% Suspension 10ml Bottle24.02USD bottle
Solu-medrol (pf) 500 mg vial20.9USD vial
PrednisoLONE Sodium Phosphate 1% Solution 5ml Bottle19.99USD bottle
Methylprednisolone Sod Succin. 500 mg/vial19.48USD vial
PrednisoLONE Acetate 1% Suspension 5ml Bottle15.99USD bottle
Solu-Medrol Act-O-Vial 125 mg/vial15.94USD vial
Solu-medrol 500 mg vial12.9USD vial
Depo-medrol 80 mg/ml vial11.67USD ml
Depo-Medrol 80 mg/ml11.51USD ml
Pred forte 1% eye drops10.32USD ml
Methylprednisolone Acetate 80 mg/ml9.01USD ml
Methylprednisolone Sod Succin. 125 mg/vial8.9USD vial
Depo-Medrol (Preserved) 80 mg/ml8.89USD ml
Orapred odt 30 mg tablet8.34USD tablet
Orapred odt 15 mg tablet7.97USD tablet
Methylprednisolone Acetate (P) 80 mg/ml6.97USD ml
Omnipred 1% eye drops6.78USD ml
Solu-Medrol Act-O-Vial 40 mg/vial6.72USD vial
Depo-medrol 40 mg/ml vial6.41USD ml
Depo-Medrol 40 mg/ml6.01USD ml
Pred Forte 1 % Suspension5.95USD ml
Solu-medrol (pf) 125 mg vial5.83USD vial
Depo-Medrol (Preserved) 40 mg/ml5.75USD ml
Prednisolone ac 1% eye drop5.75USD ml
Prednisol 1% eye drops5.69USD ml
Pred mild 0.12% eye drops5.14USD ml
Medrol 32 mg tablet5.13USD tablet
Methylprednisolone Acetate 40 mg/ml4.71USD ml
Methylprednisolone Acetate (P) 40 mg/ml4.5USD ml
Econopred plus 1% eye drops3.93USD ml
Orapred odt 10 mg tablet3.89USD tablet
Depo-medrol 20 mg/ml vial3.78USD ml
Methylprednisolone Sod Succin. 40 mg/vial3.77USD vial
Prednisolone sod 1% eye drops3.7USD ml
Medrol 16 mg tablet3.5USD tablet
Prednisolone acetate powder3.36USD g
Prednisolone powder3.36USD g
Depo-Medrol 20 mg/ml2.63USD ml
Medrol 8 mg tablet2.3USD tablet
Ratio-Prednisolone 1 % Suspension2.03USD ml
Sandoz Prednisolone Acetate 1 % Suspension2.03USD ml
Pred Mild 0.12 % Suspension2.02USD ml
Medrol 4 mg tablet1.69USD tablet
Medrol 4 mg dosepak1.59USD each
Sandoz Prednisolone Acetate 0.12 % Suspension1.33USD ml
Millipred dp 5 mg dose pack tablet1.18USD tablet
Medrol 2 mg tablet0.84USD tablet
Orapred 15 mg/5 ml solution0.74USD ml
Millipred 5 mg tablet0.59USD tablet
Prelone 15 mg/5 ml syrup0.54USD ml
Prelone 15 mg/5ml Syrup0.47USD ml
PrednisoLONE Sodium Phosphate 15 mg/5ml Solution0.33USD ml
PrednisoLONE Sodium Phosphate 5 mg/5ml Solution0.23USD ml
Prednisolone 5 mg tablet0.14USD tablet
Pediapred 1 mg/ml Liquid0.14USD ml
Pms-Prednisolone 1 mg/ml Liquid0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5178878No1993-01-122010-01-12Us
US6221392No1998-04-092018-04-09Us
US6024981No1998-04-092018-04-09Us
US6740341No1999-11-242019-11-24Us
US7799331No2008-10-112028-10-11Us
US6071523No1998-06-032018-06-03Us
US6399079No1998-06-032018-06-03Us
US5881926No1996-03-162016-03-16Us
US6656482No1998-06-032018-06-03Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)235 °CPhysProp
water solubility223 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.62HANSCH,C ET AL. (1995)
logS-3.21ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.239 mg/mLALOGPS
logP1.66ALOGPS
logP1.27ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.58ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity98.49 m3·mol-1ChemAxon
Polarizability38.78 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9918
Blood Brain Barrier+0.9383
Caco-2 permeable-0.5096
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor INon-inhibitor0.7847
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7463
CYP450 2C9 substrateNon-substrate0.8496
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9406
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9418
CYP450 2C19 inhibitorNon-inhibitor0.9253
CYP450 3A4 inhibitorNon-inhibitor0.8902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9095
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9597
BiodegradationNot ready biodegradable0.925
Rat acute toxicity1.8914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.95
hERG inhibition (predictor II)Non-inhibitor0.584
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-00di-1910000000-2f59b266e7257ff0e7ad
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0019000000-34782b355045c38d0504
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-002f-0009000000-4a00ac3c2f4930e108cc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0005-0689000000-b0eaba9949ae34d0e571
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-0a92fbafb31c0170151c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-856481c7f4d3a6d1ac63
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-813955b7791f046a3a67
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-c70a1009bba6e4f3a2c8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0006-0009000000-e4bce0d078573494d8cd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-006w-0905000000-94eb00e6ffa4c56ac51b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-7797dc6be351391cf57a
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00dj-0900000000-d156992d517e46c9575d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00r2-0910000000-598b90f7f0f7ba4e13eb
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00di-0900000000-eed30fed077e1dfffd3b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-002f-0009000000-0af4f657def15fe9274e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-1920000000-5811b59a6f57222762d7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-06xw-2910000000-84fec77617e1b7a1648b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03dl-0596000000-e0abadaf09054d046b08
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03xu-0595000000-4f8d30df506ea649fc04
MS/MS Spectrum - , positiveLC-MS/MSsplash10-006x-1986000000-d088900fa4c56b9ff51d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0159-0900000000-01f9c0e6f14839685506

Taxonomy

Description
This compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Hydroxysteroids
Direct Parent
21-hydroxysteroids
Alternative Parents
Gluco/mineralocorticoids, progestogins and derivatives / 20-oxosteroids / 3-oxo delta-1,4-steroids / 17-hydroxysteroids / 11-beta-hydroxysteroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Secondary alcohols / Cyclic ketones
show 4 more
Substituents
Progestogin-skeleton / 21-hydroxysteroid / 20-oxosteroid / Pregnane-skeleton / 3-oxo-delta-1,4-steroid / 3-oxosteroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid / 17-hydroxysteroid
show 15 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
11beta-hydroxy steroid, 17alpha-hydroxy steroid, glucocorticoid, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, 21-hydroxy steroid (CHEBI:8378) / Pregnane and derivatives [Fig] (C07369) / C21 steroids (gluco/mineralocorticoids, progestogins) and derivatives (LMST02030179)

Targets

Details
1. Glucocorticoid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Zinc ion binding
Specific Function
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
Gene Name
NR3C1
Uniprot ID
P04150
Uniprot Name
Glucocorticoid receptor
Molecular Weight
85658.57 Da
References
  1. Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Andreadou I, Nikolaou M, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos P, Kremastinos DT: Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. 2009 Sep;95(18):1502-7. doi: 10.1136/hrt.2009.168971. Epub 2009 May 28. [PubMed:19482847]
  2. Boudinot FD, D'Ambrosio R, Jusko WJ: Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm. 1986 Oct;14(5):469-93. [PubMed:2879901]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Litt J. (2016). Litt's Drug eruption & reaction manual (22nd ed.). CRC Press LLc.
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Steroid binding
Specific Function
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name
SERPINA6
Uniprot ID
P08185
Uniprot Name
Corticosteroid-binding globulin
Molecular Weight
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Frey BM, Frey FJ: Estimation of transcortin concentration by measurements of plasma protein-binding of prednisolone and by electroimmunodiffusion. Br J Clin Pharmacol. 1982 Feb;13(2):245-9. [PubMed:6800390]
  4. Ko HC, Almon RR, Jusko WJ: Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats. Pharm Res. 1995 Jun;12(6):902-4. [PubMed:7667198]
  5. Angeli A, Frajria R, De Paoli R, Fonzo D, Ceresa F: Diurnal variation of prednisolone binding to serum corticosteroid-binding globulin in man. Clin Pharmacol Ther. 1978 Jan;23(1):47-53. [PubMed:563315]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
Gene Name
SLCO1A2
Uniprot ID
P46721
Uniprot Name
Solute carrier organic anion transporter family member 1A2
Molecular Weight
74144.105 Da
References
  1. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019]
  2. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924]

Drug created on June 13, 2005 07:24 / Updated on August 14, 2018 04:32